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There has been an explosion of literature focusing on the role 
of regulatory T (Treg) cells in cancer immunity. It is becoming 
increasingly clear that Treg cells play an active and significant 
role in the progression of cancer, and have an important role 
in suppressing tumor-specific immunity. Thus, there is a clear 
rationale for developing clinical strategies to diminish their 
regulatory influences, with the ultimate goal of augmenting 
antitimor immunity. Therefore, manipulation of Treg cells rep-
resent new strategies for cancer treatment. In this Review, I 
will summarize and review the explosive recent studies dem-
onstrating that Treg cells are increased in patients with ma-
lignancies and restoration of antitumor immunity in mice and 
humans by depletion or reduction of Treg cells. In addition, I 
will discuss both the prognostic value of Treg cells in tumor 
progression in tumor-bearing hosts and the rationale for 
strategies for therapeutic vaccination and immunother-
apeutic targeting of Treg cells with drugs and microRNA.
[Immune Network 2009;9(6):209-235]
INTRODUCTION
It is well established and generally accepted that numerous 
innate and adaptive immune effector cells and molecules par-
ticipate in the recognition and destruction of cancer cells, a 
process that is known as cancer immunosurveillance. Howev-
er, cancer cells avoids such immunosurveillance through the 
outgrowth of poorly immunogenic tumor -cell variant (immu-
noselection, a process that is also known as immunoediting) 
and through immunosubversion (1,2) The immune system in-
teracts  with  tumors  throughout  their  development,  and  the 
consequences of this interaction have substantial implications 
for cancer therapy. Although some host responses may inhibit 
tumor growth and progression, the immune system can also 
promote cancer by provoking chronic inflammation and, in 
turn,  elaborating  factors  that  drive  tumor  growth,  survival, 
and angiogenesis. Failure of immunity can predispose a per-
son  to  tumor  development  (3).  T  cell-mediated  immuno-
suppression  has  been  observed  for  decades  without  clar-
ification  as  to  which  factors  was  responsible  for  this 
observation. Recently, a number of publications showed that 
progressive  tumor  growth  evokes  generation  of  immuno-
suppressor  cells  and  suppressor  T  cells  (4,5).  The  identi-
fication of regulatory T (Treg) cells represents a milestone in 
the  field  of  immuology  and  provides  an  explanation  for 
T-cell-mediated  immunosuppression  (6-11).  Although  Treg 
cells were originally identified for their ability to prevent or-
gan-specific autoimmune disease in mice, emerging evidence 
suggests that Treg cells play a pivotal role in tumor immunol-
ogy and contribute to tumor growth and progression, thereby 
having  an  important  impact  on  the  outcome  of  cancer  pa-
tients  (3,12-17).  Likewise,  tumor-induced  immune  suppre-
ssion could be responsible for the failure of many promising 
c e l l - b a s e  v a c c i n e  a t t e m p t s  ( 1 8 )  a n d  o t h e r  i m m u n e - b a s e d  
therapies  against  cancer  (2,3,15,19-21).  Tumor-induced  im-
mune suppression is caused by numerous mechanisms, many 
of which involve the accumulation of immune-suppressive in-
filtrates in the tumor microenvironment. One of the most po-
tent and well-studied suppressive phenotypes found in the tu-
mor microenvironment is the Treg cells. Increasing evidence 
shows that Treg cell may also play an important role in im-
mune evasion mechanisms employed by cancer (17,18,22-24). 
Tumors may differentiate, expand, recruit, and activate Treg 
(tumor Treg) cells via multiple mechanisms and potently ab-
rogate antitumor immunity (25,26). Fig. 1 shows a schematic Regulatory T Cell in Cancer
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Figure 1. Tumor-mediated genera-
tion of regulatory T (Treg) cells and 
the effect on the tumor micro-
environment. Tumor cells induce 
the generation of Treg cells through
both cell contact-dependent and 
cell contact-independent mechani-
sms. Soluble protein such as TGFβ
produced by tumor cells promote 
the proliferation of Treg cells and 
induce the conversion of naive 
CD4＋CD25- T cells into Treg cells.
Tumor cells also express costimula-
tory molecules such as CD80/ 
CD86 or CD70 and interact with 
naive T cells to convert these naive
T cells into Treg cells. The in-
creased numbers of Treg cells 
inhibit the NK cells, CD4＋ T cells,
CD8＋T cells and the other cells 
and contribute to the progression of 
tumors.
diagram of tumor-mediated generation of Treg cells in tumor 
microenvironment. Tumor Treg cells may promote local tu-
mor growth at tumor site, and may be relevant to the pro-
gression of systemic disease in the peripheral blood or lym-
phoid organs (25,27,28). Thus, tumor Treg cells may be a ma-
jor  obstacle  for  immunoterapy  of  cancer  (25,27,29,30). 
Elucidating the mechanisms by which these cells traffic and 
accumulate in the tumor microenvironment could provide at-
tractive  therapeutic  targets  with  which  to  combat  tumor-in-
duced immune suppression (11,31,32). An emerging interest 
is the potential role of Treg cells in cancer development and 
progression because they have been shown to suppress anti-
tumor immunity (11,33). Thus, the critical role of Treg cells 
in  tumor  immunotherapy  has  been  gradually  elucidated 
(28,29,34,35).  Treg  cells  (defined  as  CD4＋CD25＋FoxP3＋ 
T cells) have been shown to be inversely related to the out-
come  of  several  human  malignancies  (26,36-41).  Further-
more, depletion of Treg cells can enhance rejection of endog-
enous  immune  mediated  tumor  and  improve  tumor  anti-
gen-specific  immunity,  which  highlights  the  impact  of  Treg 
cells in antitumor immunity (28,42,43) Depletion of Treg cells 
has also been shown to improve the efficacy of tumor im-
munotherapy,  including  vaccination  and  CTLA4  blockade 
(28-30,44).
    In this review, I will discuss the role of human Treg cell 
in cancer. With this in mind, I briefly outline the evidence 
describing  the  role  of  Treg  cell  in  impairing  antitumor  im-
mune responses. And, I will review the recent studies demon-
s t r a t i n g  t h a t  T r e g  c e l l s  a r e  i n c r e a s e d  i n  p a t i e n t s  w i t h  
malignancies.  I  will  also  review  the  effects  of  depletion  or 
reduction of Treg cells on tumor progression and alterations 
of Treg homeostasis by cancer treatment. In addition, I will 
discuss both the prognostic value of Treg cells in tumor pro-
gression  or  survival  of  tumor-bearing  animals  and  humans 
and the rationale for clinical use of Treg cells. It will empha-
size the difficulties, as well as the opportunities, encountered 
in  transitioning  from  bench  to  bedsides.  I  will  confine  this 
discussion to CD4＋CD25＋ or CD4＋CD25＋FoxP3＋ Treg 
cells that develop in both the thymus and periphery and rep-
resent the major Treg cell populations that act critical for im-
mune homeostasis (45). FoxP3
−iTreg cells such as Tγ1 and 
Th3  cell  will  not  be  discussed  here.
Treg CELLS
There has been an explosion of literature focusing on the role 
of these cells in several settings including cancer immunity, 
autoimmunity,  transplantation  tolerance  allergic  responses 
and  microbial  immunity  (reviewed  in  9,12-14,46-48).  Treg 
cells can be described as a T-cell population that functionally 
suppresses  an  immune  response  by  influencing  the  activity 
of another cell type (49,50). Treg cells were initially described 
by  Gershon  et  al  (6,7)  in  the  early  1970s  and  were  called 
suppressor T cells. Thereafter, a series of papers concerning 
thymic suppressor cell which could inhibit cell-mediated im-
munity in many different in vivo models (51-55). Unfortunate-
ly,  despite  the  importance  of  these  studies  there  was  ex-
tensive skepticism in the immunological field about existence Regulatory T Cell in Cancer
Tai-You Ha
211 IMMUNE NETWORK http://www.ksimm.or.kr Volume 9 Number 6 December 2009
of these cell, and suppressor T cells left the center stage of 
immunology  for  decades.  However,  a  rejuvenation  of  the 
Treg  field  was  launched  through  the  work  of  Sakaguchi  et 
al (10,11) who in 1995 reported that a small group of T cells 
with  particular  cell  surface  phenotype  (CD4＋ cells  which 
co-express the IL-2 receptor-α chain, CD25) maintain self-tol-
erance  and  that  breakdown  of  this  tolerance  could  lead  to 
autoimmune disease and CD4＋CD25＋ T cells were named 
Treg cells. Now the terms “suppressor T cells” and “regulato-
ry T cells” are used interchangeably, but the term “regulatory 
T cells” is preferred by most researchers. Work in the field 
of  Treg  cell  immunology  was  greatly  enhanced  in  2003  by 
the discovery and characterization of the Treg-specific gene, 
FoxP3 (45,56-59). So far the most specific marker for naturally 
occurring CD4＋ Treg cells, at least in mice, is FoxP3, a mem-
ber of the forkhead family of DNA-binding transcription factor 
(45,56,58,59). More recent studies have shown that FoxP3 is 
not only a key intracellular marker but is also a crucial devel-
opment  and  functional  factor  for  CD4＋CD25＋ Treg  cells 
(45,59-61). Until now, there are at least three recognized sub-
sets of CD4＋ Treg cells involved in the negative regulation 
of immune response, which include CD4＋CD25＋ FoxP3＋, 
type 1 Treg cells (Tγ1) secreting IL-10 and Th3 cells secret-
ing TGFβ (62-66). Among these, classical Treg cells are CD4
＋CD25＋FoxP3＋ T  cells  and  depletion  of  CD4＋CD25＋ 
FoxP3  cells  has  attracted  much  attention  in  recent  years 
(28,29,58,67,68). Treg cells, according to their sources, broad-
ly belong to two classes, which are naturally occurring thy-
mic-derived Treg cells and adaptive or inducible Treg cells. 
Naturally  occurring  Treg  (nTreg)  cells  are  generated  in  the 
thymus  during  development  of  T  lymphocytes  (62,63,69). 
These Treg cells, constituting 5-10% total lymphocytes, then 
enter peripheral circulation and are widely distributed in pe-
ripheral  reservoir  lymph  nodes  and  spleens  (63,64,70).  On 
the contrary, adaptive or inducible Treg (iTreg) cells are de-
v el op ed  in  t he  pe ri ph er y f ro m n ai ve  T c e lls  or  nT re g  ce ll s 
under  the  influence  of  various  inductive  signals,  most  im-
portantly TGFβ or IL-10 (54,62,63,69,71). Treg cells are pri-
marily  characterized  by  CD4＋FoxP3＋ or  CD4＋CD25＋
FoxP3  T  cells  and  FoxP3  has  been  considered  as  a  master 
regulatory transcription factor for Treg cells (45,56,58,59). It 
has recently been reported that FoxP3＋ Treg cells could also 
be generated outside the thymus under a variety of conditions 
(54,59,72). It has become evident that FoxP3＋ Treg cells are 
one  of  the  main  barrier  to  implementation  of  cancer  im-
munotherapies (12,21). Tumor tissue promote the conversion 
of naive T cells into FoxP3 Treg cells and accumulation of 
Treg cells in tumor site, thereby impairing the development 
of effector responses (33,60,61). Thus, FoxP3＋ Treg cells ha-
v a  a  k e y  f u n c t i o n  i n  o b s r u c t i n g  t u m o r  i m m u n o s u r v e i l l a n c e  
(33,57,73). Although nTreg cells develop in the thymus, sev-
eral reports have demonstrated that peripheral CD4＋CD25＋ 
T  cells  can  be  converted  into  adaptive  FoxP3＋Treg  cells 
(74,75). Among the other major surface markers, glucocorti-
coid-induced TNF-receptors-related (GITR) protein and cyto-
toxic lymphocyte-associated angigen-4 (CTLA-4) are the most 
important with respect to development and function of Treg 
cells (45,47,48,69). Intrestingly, it has been reported that the 
large number of different cell types that are purported to be 
directly targeted by FoxP3＋ Treg cells are CD4＋, CD8＋ T 
cell,  dendritic  cells,  B  cells,  marophages,  osteoblasts,  mast 
cells,  NK  cells,  and  NKT  cells  (45).
INCREASED PREVALENCE OF Treg CELLS IN 
CANCER BEARING MICE
Recently, in murine models, a vast numbers of murine studies 
have shown that prevalence of Treg cells is increased in tu-
mor bearing mice and the depletion or inhibition of Treg cells 
can enhance antitumor immunity (76-78). In context of can-
cer, Treg-cell frequencies and function are important because 
increased number might favor tumor development or growth 
and  influence  the  course  of  the  disease.  It  has  been  also 
shown that CD8＋ T cell immunity against a tumor or self-an-
tigen is hindered by Treg cells and Treg cells inhibit adoptive 
immunotherapy  in  pme-l  TCR  transgenic  mice  (77).  In  a 
mouse pancreas cancer model, tumor actively promotes the 
accrual of Treg through several mechanisms involving activa-
tion  of  nTreg  cells  as  well  as  conversion  of  non-Treg  into 
Treg cells (78). Both antitumor effector T cells and Treg cells 
capable of abrogating the antitumor reactivity of the effector 
T cells are primed in the same tumor-draining lymph nodes 
during tumor progression and the Treg cells generated in tu-
mor-draining lymph nodes possess the same functional prop-
erties as the Treg cells that arise naturally in the thymus but 
recognize  tumor-associate antigen (79). One  study reported 
that  the  numbers  of  FoxP3＋CD4＋nTreg  cells  are  sig-
nificantly increased in draining but not non-draining, lymph 
nodes and spleen of tumor-bearing mice (80). In this study, 
f u r t h e r m o r e ,  a  s m a l l  n u m b e r  o f  n T r e g  c e l l s  c o u l d  b e  a l s o  
found  at  the  tumor  sites.  In  a  transgenic  mouse  model  of 
prostate  dysplasia,  functional  studies  confirmed  a  role  for Regulatory T Cell in Cancer
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CD4＋CD25＋ Treg cells in suppressing T cell proliferation 
as well as regulating the growth of transplanted prostate tu-
mor  cells  (81).  Additionally,  these  studies  showed  that  an-
ti-CD25 antibody treatment reduces, but does not prevent, tu-
mor growth in a transgenic mouse model of prostate dyspla-
sia, These transgenic mouse developed reproducible prostate 
s p e c i f i c  t u m o r s  t h a t  c a n  p r o g r e s s  t o  m o u s e  p r o s t a t i c  i n t r a -
epithelial neoplasia similar to human prostatic intraepithelial 
neoplasia (81). Interestingly, in the mouse tumor model, no 
difference was observed in the proportion of CD4＋CD25＋
/CD4＋ in peripheral blood lymphocytes between colon-car-
cinoma-bearing BALB/c mice and normal mice, while there 
was a significant increase in the proportion in spleen lympho-
cytes in tumor bearing mice as compared with normal mice 
(82). Moreover, the proportion increased in accordance with 
the  increase  in  the  tumor  size,  suggesting  that  the  CD4＋
CD25＋/CD4＋ proportion in  spleen lymphocytes might be 
a sensitive index to evaluate the Treg cell in tumor mouse 
models. In one study, the transforming growth factor-β (TGF
β) secreting murine pancreas adenocarcinoma (Pan02) cell 
line was injected into syngeneic C57BL/6 mice. and the prev-
a l e n c e  o f  T r e g  c e l l s  i n  t h e  t u m o r  d r a i n i n g  l y m p h  n o d e s  
(TDLNs) and spleen was measured weekly. Compared with 
control mice, the prevalence of CD4＋CD25＋ Treg cells in 
TDLNs  and  in  tumor  spleen  increased  with  tumor  growth, 
providing  evidence  that  Pan02  tumor  promotes  the  preva-
lence  of  Treg  cells  (32).
    A study showed, using murine colorectal tumor, that tumor 
immunity stimulated in the absence of regulatory cells is not 
restricted  to  tumors  of  colorectal  origin,  but  is  effective 
against tumors of different histological types such as B cell 
lymphoma and a renal cell carcinoma (83). The data suggest 
that the generation of cross-reactive tumor immunity is a spe-
cific manifestation of CD25 Treg cell depletion and the gen-
eration of CD4＋ T cells capable of mediating tumor rejection 
is  another  important  feature  of  tumor  immunity  induced  in 
the absence of CD25＋ cells. Interestingly, Ghiringhelli et al 
investigated the mechanisms of immune tolerance raised by 
tumors  by  comparing  immunogenic  and  tolerogenic  tumor 
cell clones isolated from a rat colon carcinoma (84). When 
injected  into  syngeneic  hosts,  the  immunogenic  REGb  cells 
yield  tumors  that  are  rejected,  while  the  tolerogenic  PROb 
cells  yield  progressive  tumors  and  inhibit  the  regression  of 
REGb tumors (84). They found that PROb tumor volume is 
correlated with an expansion of CD4＋CD25＋ Treg cells in 
lymphoid tissues. While total T cells from PROb tumor-bear-
ing rats yield no apparent antitumor immune response, deple-
tion of CD25＋ T cells restores this reactivity. A single admin-
istration  of  cyclophosphamide  depletes  CD4＋CD25＋ Treg 
cells  in  PROb  tumor-bearing  animals,  delays  the  growth  of 
PROb tumors, and cures rats bearing established PROb tumor 
when  followed  by  an  imunotherapy  which  has  no  curative 
effect when administered alone. These data strongly suggest 
that  role  of  Treg  cells  in  tumor-induced  immune  tolerance 
and the interest of Treg cell depletion to sensitize established 
tumors to immunotherapy. Interestingly, furthermore, a recent 
study  demonstrated  the  role  of  Treg  cells  in  tumors  of  the 
central nervous system (85). The authors implanted syngeneic 
GL26 tumor cells in the brain of C57BL/6 mice, and tumor-in-
filtrating  lymphocytes  (TILs)  was  analyzed  and  found  that 
CD4＋CD25＋ Treg cells play an important role in suppress-
ing the immune response to tumors of central nervous sys-
tem, suggesting that these Treg cells may therefore represent 
a  potentially  novel  target  for  immunotherapy  of  malignant 
glioma. Schabowsky et al showed that Treg cells are actively 
recruited and induced by tumors to block innate and adaptive 
immune  priming,  effector  function  and  memory  response 
which can inhibit the efficacy of therapeutic cancer vaccines 
(18). Combination of CTLA-4 blockade and depletion of CD25
＋ Treg  cells  results  in  maximal  tumor  rejection  (86).  The 
synergism in the effects indicates that CD25＋ Treg cells and 
CTLA-4 signaling represent two alternative pathways for sup-
pression of autoreactive T cell immunity, suggesting that si-
multaneous intervention with both regulatory mechanisms is 
therefore a promising concept for the induction of therapeutic 
antitumor  immunity.
    It has been reported that cyclooxygenase (COX)-2 and its 
product prostaglandin (PG)E2 underlie an immunosuppressive 
network  that  is  important  in  the  pathogenesis  of  non-small 
cell  lung  cancer  (86).  Tumor-derived  COX-2/PGE2  induced 
expression  of  the  Treg  cell-specific  transcription  factor, 
FoxP3,  and  increased  Treg  cell  activity.  In  vivo, COX-2 in-
hibition reduced Treg cell frequency and activity, attenuated 
FoxP3 expression in TILs and decreased tumor burden, pro-
viding  evidence  that  inhibition  of  COX-2/PGE2  suppresses 
Treg  cell  activity  and  enhances  antitumor  responses  (87).
    Concomitant  tumor  immunity  describes  the  immune  re-
sponse in a host bearing a progressive tumor that rejects an 
inoculum of the same tumor at distant site (34,88). Progres-
sion of poorly immunogenic B16 melanoma did not sponta-
neously  elicit  concomitant  immunity  (88).  However,  deple-
tion of CD4＋ T cells in tumor-bearing mice resulted in CD8Regulatory T Cell in Cancer
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＋ T cell-mediated rejection of challenge tumors. Concomi-
t a n t  i m m u n i t y  w a s  a l s o  e l i c i t e d  b y  t r e a t m e n t  o f  c y c l o p h o s-
mamide.  nTreg  cell  efficiently  suppressed  concomitant  im-
munity mediated by previously activated CD8＋ T cells (88). 
These  results  shows  that  Treg  cells  are  the  major  regulator 
of concomitant tumor immunity against weakly immunogenic 
tumor.  In  a  series  of  elegant  studies,  most  recently,  Lin  et 
al found that CD8＋ T cells, from mice that lost concomitant 
tumor immunity, possessed potent antitumor properties and 
strongly expressed effector molecules (34). Furthermore, in-
terestingly, effector/memory Treg cells increased as the pri-
mary tumor progressed. They also reported that these effec-
tor/memory Treg cells inhibit concomitant tumor immunity in 
vivo. Their data suggest that effector/memory Treg cells are 
responsible for the loss of concomitant tumor immunity asso-
ciated  with  tumor  progression.
    Valzasina et al reported that tumor injection in thymectom-
ized  and  CD25-depleted  mice  shows  that  CD4＋CD25＋ 
T-cell expansion occurs even in the absence of thymus (74). 
These  newly  generated  cells  are  bonna  fide T r e g  c e l l s  i n  
terms of FoxP3 expression. In addition, they analyzed Treg 
cell number and function in tumor-bearing mice as well as 
their recovery after peripheral and central depletion by means 
of  anti-CD25  monoclonal  antibody  (mAb)  and  thymectomy, 
and  described CD4＋CD25-T-cell conversion into Treg cells 
as the main mechanism of Treg cell replenishment and ex-
pansion  in  tumor-bearing  mice.
  Recently, there is a large number of evidence illustrating 
the increase in the number of Treg cells in the tumor setting, 
but very little work has been done to address the functionality 
of  these  cells.  Despite  the  numerous  studies  showing  that 
Treg cell from tumor-bearing animals and cancer patients are 
functional, no studies have directly compared Treg cells from 
tumor-bearing and nontumor-bearing animals. A recent study 
directly compared Treg cells in the spleen and the tumor in-
filtrate at both the molecular and functional levels (89). This 
study provides evidence that tumor-infiltrating Treg cells are 
functionally impaired, due to a loss of ability to respond to 
TCR stimulation and that murine Treg cells in the tumor mi-
croenvironment display both enhanced proliferation and re-
duced functionality. This enhanced proliferation leads to an 
intratumoral accumulation of Treg cells with a unique pheno-
type:  CD4＋CD25＋FoxP3＋GITR
highCD27l
lowCD621L
−.  The 
data further demonstrate that the accumulation of Treg cells 
in the tumor is caused by multiple factors, including increased 
proliferation,  decrease  apoptosis ,  a n d  a l t e r e d  e x p r e s s i o n  o f  
chemokines,  chemokine  receptor,  and  cell-surface  markers. 
The trafficking of T cells is mediated in part by chemokines 
and the expression of their receptors. Higher expression of 
the  chemikine  receptor  CCR4  was  reported  on  Treg  cells. 
Likewise, CCR4 associated chemokines and macrophage-deri-
ved chemokine (CCL22) have been correlated with higher fre-
quencies of Treg cells in gastric cancer (90). In ovarian can-
cer, tumor-derived CCL22 was shown to recruit Treg cells in 
vivo an d p re di ct s a  ne g at iv e  pro gnosis  (91).  Most  recently, 
Mailloux et al examined Treg cell levels and changes in che-
mokine secretion in a murine model of Lewis lung carcinoma 
(LLC) and demonstrated increased number of CD4＋CD25＋ 
FoxP＋ T r e g  c e l l s  i n  t h e  l u n g s  o f  C 5 7 B L / 6  m i c e  b e a r i n g  a 
metastatic  LLC  (31).
  It has been recently reported that in a syngeneic murine 
glioma  model  a  time-dependent  accumulation  of  CD4＋
FoxP3 Treg cell in brain tumor (92). Further analysis revealed 
a time-dependent upregulation of CD25, CTLA-4, GITR on in-
tratumoral  CD4＋FoxP3＋ Treg  cells  during  tumor  growth. 
Moreover,  treatment  with  anti-CD25  mAbs  significantly  re-
duced  the  number  of  these  highly  suppressive  Treg  cells 
within the growing tumor and provoked a CD4 and CD8 T 
cell  dependent  destruction  of  the  glioma  cells.  Combining 
Treg  cell  depletion  with  administration  of  blocking  CTLA-4 
mAbs further boosted glioma-specific CD4＋ and CD8＋ ef-
fector T cells as well as antiglioma IgG2a antibody titers re-
sulting in complete tumor eradication (92). These data illus-
trate  that  intratumoral  accumulation  and  activation  of  Treg 
cells act as a dominant immune escape mechanisms for glio-
ma  and  underline  the  importance  of  controlling  tumor-in-
filtrating Treg cells in glioma immunotherapy. Most recently, 
Liu et al have beautifully investigated the suppressor function 
of both tumor and naive Treg cells in vitro and in vivo and 
r e p o r t e d  t h a t  T r e g  c e l l s  f r o m  m i c e  b e a r i n g  a  b r e a s t  t u m o r  
were  elevated (tumor Treg cells)  and that tumor Treg cells 
potently abrogate tumor-specific CD8＋ T cell response in tu-
mor-draining  lymph  nodes,  thereby  suppressing  antitumor 
immunity at the early stage of the immune response induced 
by adoptively transferred tumor-primed CD4＋ T cells (17).
RESTORATION OF ANTITUMOR IMMUNITY IN MICE 
BY DEPLETION OR REDUCTION OF Treg CELLS
As describe before, accumulating data have shown that Treg 
cells play an important role in tumor immunology. Increasing 
evidence for their role in fostering immune privilege in both Regulatory T Cell in Cancer
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mouse and human tumors has fueled interest in attempts to 
interfere with their number or function for therapeutic benefit 
(14,28). There is a large body of data in the literature demon-
strating restoration of antitumor immunity by depletion or re-
duction of Treg cells. An earlier study demonstrated that elim-
ination  of  CD25＋CD4  T  cells  can  abrogate  immunological 
unresponsiveness  to  syngeneic  tumor  in  vivo a n d  in  vitro, 
leading to spontaneous development of tumor specific effec-
tor  cells  as  well  as  tumor-nonspecific  ones  (93).  Using  the 
weakly  immunogenic  MCA205  sarcoma  and  the  poorly  im-
m u n o g e n i c  B 1 6 / B L / D 5  m e l a n o m a ,  a n  e a r l y  s t u d y  d e m o n -
strated that although the antitumor immunity enhanced by the 
depletion of CD4＋CD25＋ Treg cells is insufficient to erad-
icate tumors, it augments the sensitization of immune T cells 
in  the draining  lymph  nodes, thus,  facilitating adoptive  im-
munotherapy (94). Prasad et al showed that depletion of Treg 
cells before vaccination considerably increased the ability of 
vaccinated mice to survive tumor challenge, and allowed the 
development of long-lasting tumor protective immunity (95). 
This study suggests that it is possible to generate effective im-
munotherapeutics  against  weakly  immunogenic  tumors  by 
combining  treatment  with  dendritic  cells  (DC)  loaded  with 
apoptotic  tumor  cells  and  depletion  of  Treg  cells.  Van 
Meirvenne et al (96) described mRNA electroporation as an 
efficient gene delivery method to introduce tumor-antigen in-
to murine immature DC. They showed in this report that a 
significant improvement in cytotoxic T lymphocytes (CTL) re-
sponse is obtained both in the primary and in the memory 
effector  phases  when  Treg  cells  are  depleted  in  vivo p r i o r  
to immunization, providing the convincing evidence for the 
merit  of  Treg  cell  depletion  prior  to  immunization  with 
mRNA-electroporated DC. Onizuka et al investigated the ef-
fect  of  in  vivo  administration  of  anti-CD25  mAB  on  the 
growth of eight tumors, including five leukemias, a myeloma, 
and  two  fibrosarcoma  derived  from  four  different  inbred 
mouse strains that grew progressively in syngeneic mice (97). 
They found that a single injection of less than 0.125 mg of 
anti-CD25 mAb caused a reduction in the number of CD4＋
CD25＋cells and regression of six of the eight tumors, sug-
gesting effective tumor rejection responses resulted from de-
pletion  of Treg  cells. A study also showed that elimination 
of CD4＋ T cells by anti-CD4 antibody caused regression of 
a methylcholantrene-induced sarcoma growing in syngeneic 
A/J mice (98). A CD4＋ T-cell clone, designated T595B1, was 
also established to elucidate the characteristics of CD4＋ sup-
pressor T cells (98). Interestingly, one report has shown using 
a murine model of melanoma that treatment of mice with an-
ti-CD25 mAB facilitates long-term CD4＋ T cell-mediated tu-
mor immunity through depletion of CD25＋ Treg cells (99). 
Furthermore, depletion of CD25＋ Treg cells allows the host 
mice to induce both CD4＋ and CD8＋ antitumoral responses 
following challenge of colon cancer cells (100). Simultaneous 
depletion of CD25＋ and CD8＋ cells with mAb revealed that 
tumor-specific CD4＋ T cells were able to reject colon cancer 
cells, a MHC class II-negative tumor (100). Depletion of Treg 
cell alone or in combination wih a whole tumor cell vaccine 
promotes a tumor-specific immune response (76). Thus, strat-
egies incorporating Treg cell depletion might improve the ef-
ficacy of cancer vaccines. In addition, the suppression of anti-
tumor immunity by Treg cells occurs predominantly at the tu-
mor site, and that intratumor depletion of CD4＋ cells, even 
a t  a  l a t e  s t a g e  o f  t u m o r  d e v e l o p m e n t ,  c a n  b e  a n  e f f e c t i v e  
treatment for well-established cancers (101). IL-2-induced an-
titumor immunity is enhanced by Treg-cell depletion and is 
due to expansion of the tumor-infiltrating cytotoxic CD8＋ T 
cell  population.  More  recently,  using  B16/BL6,  a  trans-
plantable  murine  melanoma  model,  Quezada  et  al d e m o n -
strated dichotomy between the effects of Treg cell depletion 
on tumor rejection dependent on whether depletion occurs 
before (prophylactic) or after (therapeutic) tumor engraftment 
(102). In these studies, failure to promote rejection with ther-
apeutic depletion (i.e., depletion after tumor establishment, 
which is more relevant to the clinical seting) was not related 
t o  l a c k  o f  T r e g  c e l l  d e p l e t i o n ,  t o  e l i m i n a t i o n  o f  e f f e c t o r  T  
cells, or to a failure to enhance systemic antitumor T cell re-
sponses, but correlates with failure of effector cells to infiltrate 
the  tumor  and  increase  the  intratumor  ratio  of  effector  T 
cells/Treg cell, suggesting an alternative, clinically applicable 
strategy for the treatment of established tumor. In fact, care-
fully  timed  depletion  of  Treg  cells  has  been  shown  to  en-
hance  tumor  immunity.
    In  a  series  of  elegant  experiments,  Wrzesinski  et  al r e -
ported that removal of Treg cells by nonmyeloablative total 
body irradiation of tumor-bearing mice improved the function 
of  adoptively  transferred  cells  for  new  antitumor  immuno-
therapies (103). Surprisingly, they also demonstrated that su-
perior antitumor efficacy is achieved by further increasing the 
intensity of lymphodepletion to a level that required hema-
topoietic stem cells. A recent study also showed that removal 
of CD25＋ Treg cells enhanced antitimor immunity against lo-
cal  growth  of  B  cell  lymphoma  and  that  induction  or  ex-
pansion of Treg cells could be one mechanism by which the Regulatory T Cell in Cancer
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Table I. Increased prevalence of CD4＋CD25＋ regulatory T cells in patients with various cancers
Cancer type Tissues where Treg cells were detected References
Gastric cancer TDLN, TIL and PBMC 16, 23, 90, 114, 115, 116, 117, 118
Gastrointestinal cancer PBMC, tumor site and ascites 114, 117, 121, 188
Head and neck cancer PMMC 122, 123
Hepatocellular cancer PBMC and TIL, tumor tissue, and ascites 37, 124, 144, 163, 188
Melanoma PBMC, TIL and TDLN 20, 126, 127, 128, 129, 130, 131, 132, 134, 135
Pancreatic cancer PBMC 36, 136, 185
Prostate cancer PBMC, tumor site 24, 137
Renal cell cancer PBMC, Tumor site 40, 135, 139
Ovarian cancer TIL, tumor site, tumor associated lymphocytes 91, 109, 140, 141
Cervical cancer TDLN 142, 143
Endometrial cancer TDLN 143
Glioma Tumor tissue 41
Esophageal cancer PBMC, TIL 116, 117
Epithelial cancer PBMC 144
Lung cancer TIL, PBMC, tumor site, pleural effusion 109, 110, 120, 121
Breast cancer PBMC, TIL, tumor tissue 36, 119, 145, 146, 147, 148
Wilms' tumor PBMC 149
Multiple myeloma PBMC 150, 151
Adult T cell leukemia/lymphoma Tumor itself has a Treg cell phenotype 152, 153
Chronic lymphocytic leukemia PBMC 154, 155
Acute myeloid leukemia PBMC 156, 157
Non-Hodgkin lymphoma TIL 158, 159, 160
Hodgkin's lymphoma TIL 161, 162
TDLN, tumor-draining lymph nodes; PBMC, peripheral blood mononuclear cells; TIL, tumor-infiltrating lymphocytes.
growing  tumor  evades  immune  surveillance  in  mice  (104). 
Treatment of mice with low-dose of cyclophosphamide or an-
ti-25 antibody to deplete Treg cells unmasked latent T- cell 
antitumor  activity  and  tumor-located  ligation  of  CD3  and 
CD28 can activate both innate (NKT cells) and adaptive (CD4
＋ and CD8＋ T cells) responses to create a tumor-destructive 
environment to control tumor growth, but modulation of Treg 
c e l l s  i s  n e c e s s a r y  t o  u n m a s k  l o c a l  a d a p t i v e  a n t i t u m o r  r e -
sponses (105). A recent study showed that inducible and acti-
vated CD4＋CD25＋ Treg cells in the regional draining lymph 
nodes  in  mice  suppress  host  local  immunity  during  the 
growth  of  benzo[a]pyrene-induced  forestomach  carcinoma 
(106) and deletion of Treg cells can promote host local im-
munity  to  suppress  tumor  growth  (106).
  I n  a  v a r i e t y  o f  d i s e a s e  m o d e l s ,  t h e  c h e m o k i n e  r e c e p t o r s  
thus far identified as allowing Treg cells to migrate to sites 
of disease more efficiently than effector cells include CCR4, 
CCR5, CCR6, CCR7 and CCR8 (91,107). In one most recent 
study, Tan et al hypothesized that CCR5-dependent chemo-
taxis is important for Treg cell migration into pancreatic ad-
enocarinoma and that disruption of this signaling would result 
in  decrease  migration  of  Treg  cell  into  the  tumor,  thereby 
slowing tumor growth (107). In addition, they showed that 
in human and murine pancreatic adenocarcinoma, Treg cells 
found within the tumor microenvironment express CCR5 and 
demonstrated that CCR5 ligand, such as CCL5, are produced 
by the tumor cells themselves. Subsequently, they showed in 
the murine model that reduced CCL5 expression by the tumor 
results  in  decreased  Treg  cell  m i g r a t i o n  t o  t h e  t u m o r  a n d  
slowed tumor growth. This study suggests that Treg cell mi-
gration  into  tumor  microenvironment  is  mediated  by  the 
CCL5-CCR5 axis, and that blockade of this pathway could rep-
resent a novel immunomodulatory strategy for the treatment 
of  cancer.
    It has been recently reported that reduction of Treg cells 
can be exploited to provoke effective tumor immunity. Two 
cardinal  features  of  FoxP3＋ Treg  cells  are  that  they  con-
stitutively express CTLA-4 which only happens after activation 
in other T cell subsets, and that FoxP3 controls the expression 
of CTLA-4 in Treg cells. CTLA-4 is a potent negarive regulator 
of T cell immune resposnes, as illustrated by CTLA-4 knock-
out  mice  (45,56,57).  A  recent  study  showed  that  a  specific Regulatory T Cell in Cancer
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deficiency of CTLA-4 in Treg cells results in spontaneous de-
velopment of systemic lymphoproliferation, fatal T cell-medi-
ated  autoimmune  disease,  and  hyperproduction  of  im-
munoglobulin E in mice, and it also produces potent tumor 
immunity (108). Interestingly, Treg-specific CTLA-4 deficiency 
impairs in vivo and in vitro suppressive function of Treg cells, 
strongly suggesting that CTLA-4 is a key molecular target for 
controlling  Treg  cell-suppressive  function  in  both  physio-
logical and pathological immune responses including tumor 
immunity,  autoimmuniy  and  allergy  (108).
INCREASED PREVALENCE OF Treg CELLS IN 
PATIENTS WITH MALIGNANCIES
T cells with regulatory function were reported in patients with 
cancer even in the early 1990s (12-14). However, these re-
ports  were  not  followed  until  the  identification  of  CD4＋
CD25＋ Treg cells in 1995 (37). The first paper indicating the 
presence of CD4＋CD25＋ Treg cells in human tumor sam-
ples  emerged  in  2001  when  Woo  et  al r e p o r t e d  w h e n  o b-
served increased percentages of CD4＋CD25＋ cells from pa-
tients with lung or ovarian cancer (109,110). Since then, there 
has been an explosion of literature demonstrating the pres-
ence of CD4＋CD25＋ Treg cells in patients with a variety 
o f  c a n c e r s  ( s e e  T a b l e  I ) .  T r e g  c e l l s  p l a y  a n  i m p o r t a n t  r o l e 
in  the  prevention  of  antitumor  immune  responses  (15,21, 
64,93,111-113). The number of Treg cells in peripheral blood 
increases in many human cancers. The presence of the Treg 
cells is also likely to hinder the development of antitumor im-
mune  responses  following  the  delivery  of  an  immunother-
apeutic agent. For this reason, methods of abrogating the ac-
t i v i t y  o f  T r e g  c e l l s  m a y  b e  c r i t i c a l  f o r  t h e  s u c c e s s f u l  i m -
munotherapeutic  treatment  of  cancer  (89).  As  such,  modu-
lation of Treg cell functions in cancer has been studied using 
various approaches, with encouraging preclinical and clinical 
findings. A clear understanding of how immune function is 
modulated  by  tumor  cell  is  required  to  devise  strategies  to 
enhance  the  efficacy  of  such  therapeutic  intervention.
Treg cells in solid tumors
It has been  shown that patients with gastrointestinal malig-
nancies had a higher proportion of CD4＋CD25＋ T cells in 
peripheral blood (114,115). Among patients with gastric carci-
noma, those with higher percentages of CD4＋CD25＋ T cells 
had  a  poorer  prognosis  than  did  those  with  lower  per-
centages. Interestingly, CD4＋CD25＋ T cells also were pres-
ent in greater proportions in ascites from patients who had 
advanced-stage  disease  with  peritoneal  dissemination  (114, 
115). A recent study showed that the percentages of CD4＋
CD25
high T  c e l l s  i n  p e r i p h e r a l  b l o o d  m o n o n u c l e a r  c e l l s  
( P B M C s )  f r o m  p a t i e n t s  w i t h  g a s t r i c  a n d  e s o p h a g e a l  c a n c e r  
were significantly higher than those for healthy donors (116). 
Interestingly, after patients received curative resections of gas-
tric cancer, the increased proportions of Treg cells were sig-
nificantly reduced, and the levels were almost equal to those 
in normal healthy donors. A study also showed that the prev-
alence of peripheral blood CD4＋CD25＋ Treg cells in both 
gastric and esophageal cancer patients was significantly high-
er than that in healthy donors. The population of Treg cells 
in the TILs of gastric cancer patients with advanced disease 
was significantly higher than that in TILs of patients with ear-
ly-stage disease (117). Most recently, it has been shown that 
prevalence  of  Treg  cells  in  the  peripheral  blood  of  gastro-
intestinal  cancer  patients  is  significantly  higher  than  that  in 
healthy  volunteers,  even  in  the  early  stages  of  the  disease 
(23). Moreover, since Treg cell levels are significantly reduced 
a f t e r  c u r a t i v e  r e s e c t i o n ,  i t  i s  p o s s i b l e  t h a t  t u m o r  c e l l s  m a y  
have induced and expanded the Treg cell pool (23). Current-
ly, Shen et al have  characterized CD4＋CD25CD127
low/− a s 
the surface marker of Treg cells in gastric cancer (16). They 
found  that  the  frequency  of  CD4＋CD25＋CD127
low/− T r e g  
cells  in  the  peripheral  blood  of  gastric  cancer  patients  was 
significantly  higher  than  that  in  healthy  controls.  Increased 
Treg cells were also present in the tumor environment, such 
as those found in the ascites fluid, tumor tissue or adjacent 
lymph  nodes.  They  proposed  that  CD4＋CD25CD127
low/− 
can be used as a selective biomarker to enrich human Treg 
cells and also to perform functional in vitro assay in gastric 
cancer. Currently, Xu et al also have investigated the preva-
lence of Treg cells in gastrointestinal cancer patients treated 
with chemotherapy and demonstrated that not only was the 
prevalence  of  Treg  cells  in  the  peripheral  blood  of  gastro-
intestinal  cancer  patients  significantly  higher  than  that  in 
healthy donors, but it also increased in parallel with tumor 
progression (118). In addition, among patients with advanced 
disease, 3 weeks after chemotherapy, those who higher per-
c e n t a g e  o f  T r e g  c e l l s  h a d  a  p o o r e r  p r o g n o s i s .  R e c e n t l y ,  
Mizukami et al investigated the frequency of CD4＋CD25＋
FoxP3＋ Treg  cells  in  TILs,  tumor-draining  regional  lymph 
nodes, and PBMCs of patients of gastric cancer, and evaluated 
the  relationship  between  the  presence  of  CCL17-  or 
CCL22-producing cells and found that CC17 and CCl22 within Regulatory T Cell in Cancer
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the tumor are related to the increased population of FoxP3＋ 
Treg cells, with such an observation occurring in early gastric 
cancer  (90).  Most  recently,  some  studies  demonstrated  that 
CCL22 chemokines derived from a tumor induce the migra-
tion of Treg cells through CCR4, which is chemokine receptor 
for CCL22, and impair antitumor immunity in primary breast 
cancer  and  lung  cancer  (119,120).  In  patients  with  gastro-
intestinal cancer, as described previously, it has been shown 
that patients with gastrointestinal malignancies had a higher 
proportion  of  CD4＋CD25＋ T  cells  in  peripheral  blood 
(114,117). Wieczorek et al also found that Treg cell numbers 
are significantly increased in the peripheral blood of patients 
with IL-2-treated melanoma and in formalin-fixed tissue from 
patients  with  lung  and  colon  carcinoma  (121).  In  addition, 
they  also  demonstrated  that  Treg  cell  numbers  are  pre-
dictively elevated in the peripheral blood of patients with var-
ious solid tumors. Patients with squamous cell carcinoma of 
the head and neck have increased number of CD4＋CD25＋ 
FoxP3＋ Treg cells in their peripheral circulation compared 
w i t h  n o r m a l  c o n t r o l s  a n d  h a v e  a  d e p r e s s e d  a n t i t u m o r  i m -
mnity  (122,123).  In  addition,  surprisingly,  higher  Treg  fre-
quency and levels of suppression were observed in patients 
with no evident disease than in untreated patients with active 
disease (122). Of interest, a recent study showed that patients 
with hepatocellular carcinoma also have increased numbers 
of  CD4＋CD25＋ T r e g  c e l l s  i n  t h e i r  p e r i p h e r a l  b l o o d ,  s u g -
gesting the increase in frequency of Treg cells might play a 
role  in  modulation  of  the  immune  response  against  hep-
atocellular carcinoma and could be important in design of im-
munotherapeutic  approaches  (37).  Moreover,  Treg  cells  are 
associated  with  hepatocellular  carcinoma  invasiveness,  and 
intratumoral balance of regulatory and cytotoxic T cells is a 
promising independent predictor for recurrence and survival 
in hepatocellular carcinoma (124). It has been also demon-
strated that primary hepatic cancers develop in liver that is 
immunosuppressed by a marked infiltration of CD4＋CD25＋
FoxP3＋ Treg cells. A high prevalence of Treg cell infiltrating 
hepatocellular carcinoma cells is thought to be an unfavorable 
prognostic  indicator  (125).
    One line of study showed that measurement of heavy (H)- 
and  light  chain(L)-ferritin  by  ELISA  revealed  that  H-but  not 
L-ferritin was elevated in the circulation of melanoma patients 
and that the ratio of H-ferritin：L-ferritin correlated with the 
levels of Treg cells. In addition, this study revealed a marked 
increase  in  the  number  of  CD4＋CD25＋CD69-  T  cells  in 
such  patients  (126).  Several  studies  showed  that  CD4＋
CD25
high  FoxP3＋ Treg  cells  are  overrepresented  in  human 
m e t a s t a t i c  l y m p h  n o d e s  w i t h  a  2 - f o l d  i n c r e a s e d  f r e q u e n c y  
compared with both tumor-free lymph nodes (127-130) and 
that advanced melanoma is associated with increased num-
bers of circulating Treg cells and DCs and suggested that mel-
anoma induces immunosuppressive DCs and Treg cells in the 
systemic  circulation  of  the  patients  (131).  Vence  et  al a l s o  
showed the presence of tumor antigen-specific CD4＋ Treg 
cells in the blood of patients with metastatic melanoma (132). 
These Treg cells recognize a broad range of tumor antigens, 
including  gp100  and  TRP1  (melanoma  tissue  differentiation 
antigens),  NY-ESo-1  (cancer/testis  antigen)  and  survivin 
(inhibitor of apoptosis protein family antigen). They suppress 
auatologous  CD4＋CD25-  T  cell  responses  in  a  cell-contact 
dependent  manner.  Such  tumor  antigen-specific  Treg  cells 
were not detected in healthy individuals. Thus, these tumor 
antigen-specific Treg cells might represent another target for 
immunotherapy  of  metastatic  melanoma.
    Interestingly,  signal  transducers  and  activation  of  tran-
scription  (STAT)5  and  STAT3  oppose  one  another  in  regu-
lation of the reciprocal development of CD4＋CD25＋FoxP3
＋ Treg cells and a reduction in STAT3 is associated with up-
regulation of Treg cells, and STAT5 activation promotes Treg 
cell differentiation or function (133,134). The effects of IFNα 
on STAT signaling in relation to tumor Treg cells were not 
documented in humans beyond the observation that IFNα2b 
downregulates STAT3 (133,134). Wang et al investigated the 
effect of high-dose IFNα2b on regional lymph node meta-
stases of human melanoma (134). They found that IFNα2b 
upregulates STAT5 and downregulates STAT3, in conjunction 
with upregulation of Treg cells in melanoma tissues, suggest-
ing the effects of IFNα may be potentiated through interfer-
ence with the response of Treg cells and/or STAT5. A recent 
study showed that administration of high dose IL-2 in patients 
with metastatic melanoma and renal cell cancer increased the 
frequency  of  circulating  CD4＋CD25＋FoxP3＋ Treg  cells 
(135).  These  studies  suggest  that  selective  inhibition  of 
I L - 2 - m e d i a t e d  e n h a n c e m e n t  o f  T r e g  c e l l s  m a y  i m p r o v e  t h e  
therapeutic effectiveness of IL-2 administration. Nicholaou et 
al most recently showed in patients with melanoma that al-
though  strong  antibody  responses  were  mounted,  the  gen-
eration  of  delayed-type  hypersensitivity  response  was  sig-
nificantly  impaired  and  patients  with  advanced  melanoma 
had  a  significantly  higher  proportion  of  circulating  CD4＋
CD25＋FoxP3＋ Treg cells compared with those with mini-
mal residual disease (20). The prevalence of Treg cells in the Regulatory T Cell in Cancer
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peripheral  blood  of  pancreas  cancer  patients  is  increased 
when compared with normal individuals. Similarly, Treg cells 
are present in TILs and regional lymph nodes infiltrated by 
tumor. In addition, a recent study showed that the prevalence 
of  Treg  cells  was  significantly  increased  in  the  ductal  ad-
enocarcinomas compared with that in the stroma of nonneo-
plastic  inflammation  and  the  increased  prevalence  of  Treg 
cells was significantly correlated with certain clinicopathologic 
factors (136). They also showed that a better prognosis was 
observed in patients with a low prevalence of Treg cells and 
that in pancreatic ductal carcinoma, a high prevalence of Treg 
cells  seems  to  be  a  marker  of  poor  prognosis.
    In patients with prostate cancer, the prevalence of CD4＋
CD25
high Treg cells inside the prostate was significantly higher 
in the tumor compared with benign tissue from the sam pros-
tate (137). In this study, furthermore, the frequency of CD4＋
CD25
high T cells in peripheral blood was significantly higher 
in  prostate  cancer  patients  compared  with  normal  donors. 
Moreover,  CD4＋CD25＋ T  cells  from  blood  and  super-
natants from cultured prostate tumor tissue samples exhibited 
immunosuppressive function in vitro. These findings indicate 
that Treg cells are an important cellular component of ear-
ly-stage prostate tumors, and thus new therapeutic strategies 
aimed at inhibition or depletion of Treg cells may improve 
prostate cancer immunotherapy. Interestingly, a more recent 
study showed that although levels of CD4＋CD25
highFoxP3＋
Tr eg  c e lls  in  t he  p er iph e ral  bl oo d  o f pa ti en t s w it h  pro st at e 
cancer were not significantly higher than those in healthy do-
nors,  Treg  cells  in  patients  with  prostate  cancer  had  sig-
nificantly  greater  suppressive  functionality  than  Treg  cells 
from heathy donors (24). Additionally, there was a direct cor-
relation between the serum levels of PGE2 and Treg cell func-
tionality in patients with localized prostate cancers. Most re-
cently,  it  has  been  reported  that  more  than  four  hundred 
prostate cancer patients have elevated numbers of circulating 
and tumor infiltrating Treg cells and Treg cells increase tumor 
growth  in  vivo  and  these  Treg  cells  potently  inhibit  tu-
mor-specific T cells (138). In patients with renal cancer, inter-
estingly, administration of high dose IL-2 in patients with re-
nal cell cancer increased the frequency of circulating CD4＋
CD25＋Foxp3＋ Treg cells (135). These studies suggest that 
selective  inhibition  of  IL-2-mediated  enhancement  of  Treg 
cells  may  improve  the  therapeutic  effectiveness  of  IL-2 
administration. More recently, a study showed that it is the 
FoxP3- subset of CD4＋CD25＋ T cells and not the FoxP3＋ 
subset that correlated with worse pathologic feature of renal 
cell  carcinoma  and  cancer-specific  survival  (40).  Most  re-
cently, Jensen et al also reported that intratumoral FoxP3＋ 
Treg  cells  significantly  increased  during  IL-2-based  im-
munotherapy,  and  high  numbers  of  on-treatment  FoxP3＋
cells  were  correlated  with  poor  prognosis  in  patients  with 
metastatic  renal  cell  carcinoma  (139).
    In  patients  with  ovarian  cancer,  tumor-associated  T  cells 
from patients with late-stage ovarian cancer contain increased 
proportion of  CD4＋CD25 T cells and may be contributing 
to T-cell immune suppression (109). In addition, a study also 
showed that there is an increasing of the proportion of CD4＋
CD25＋ Treg cells in PBMC, TIL and tumor associated lym-
phocytes of the patients with ovarian carcinoma (140). In a 
large scale study of 104 patients with ovarian carcinoma, CD4
＋CD25＋FoxP3＋ Treg cells were shown to accumulate in 
tumors, in which they suppressed tumor-specific T cell im-
munity (91). In this study, most notably, the numbers of Treg 
cells present within tumor biopsy specimens of different pa-
tients  was  highly  inversely  correlated  with  patient  survival. 
Tumor  cells  and  microenvironmental  macrophage  produce 
the  chemokine  CCL22,  which  mediates  trafficking  of  Treg 
cells to the tumor. These studies provide evidence that this 
specific recruitment of Treg cells represents a mechanism by 
which tumor may foster immune privilege and blocking Treg 
cell migration or function may help to defeat human cancer 
(91). Most recently, one line of evidence showed that disease 
specific survival was not influenced by the presence of FoxP3
＋ Treg cells in ovarian tissue, but median disease specific 
survival of patients with a high CD8＋/FoxP3＋ ratio in ovar-
ian-derived  tumor  tissue  was  twice  as  high  as  for  patients 
with a low CD8＋/FoxP3＋ ratio (141). Possibly, the positive 
prognostic effect of the of FoxP3＋ cells in their samples can 
be attributed to the staining of not only suppressive, but also 
activated T cells expressing FoxP3. In patients with cervical 
carcinoma,  all TDLN  contained Treg  cells  whose  frequency 
and  suppressive  function  was  not  influenced  by  the  neo-
adjuvant therapy (142,143). These studies showed that neo-
adjuvant  therapy  produces  an  enhancing  effect  on  the  im-
m u n e  c o m p e t e n c y  o f  T D L N s  f r o m  p a t i e n t s  w i t h  c e r v i c a l  
carcinoma.  In  endometrial  cancer  patients,  similarly,  Treg 
cells  were  observed  in  TDLN  (143).
    Of great interest, in malignancies of intrinsic central nerv-
ous system, Heimberger et al have recently shown that Treg 
cells were not present in normal brain tissue and were very 
rarely  found  in  low-grade  gliomas  and  oligodendrogliomas 
(41). They observed significant differences in the prevalence Regulatory T Cell in Cancer
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of Treg cells between astrocytic and oligodendorglial tumors, 
between  different  pathologic  types  of  tumors.  In  addition, 
they identified Treg cells most frequently in glioblastoma mul-
tiforme  but  very  rarely  in  low-grade  astrocytomas.  Further-
more, they also observed that the presence of Treg cells with-
in glioblastoma multiformes did not alter the median survival 
in patients from whom the tumors were obtained. These re-
sults  strongly  suggest  that  Treg  infiltration  differed  signifi-
cantly  in  the  tumors  according  to  lineage,  pathology,  and 
grade, and that Treg cells seemed to have the highest predi-
lection for tumors of the astrocytic lineage and specifically in 
the  high-grade  gliomas,  such  as  glioblastoma  multifmorme. 
The  authors  noted  that  the  presence  of  Treg  cells  in  glio-
blastome multiformes seemed to be prognostically neutral. A 
study  also  showed  that  the  prevalence  of  peripheral  blood 
CD4＋CD25＋ Treg cells in esophageal cancer patients was 
significantly higher than that in healthy donors (117). In addi-
tion,  Kono  et  al s h o w e d  t h a t  t h e  p e r c e n t a g e s  o f  C D 4 ＋
CD25
high T cells in PBMCs from patients with esophageal can-
cer  were  significantly  higher  than  those  for  healthy  donors 
(116). One study provided evidence of an increased pool of 
CD4＋CD25＋ Treg  cells in  the  peripheral  blood  of cancer 
patients, including lung cancer, breast cancer, colorectal can-
cer and gastiric cancer patients with potent immunosuppre-
ssive features (144). In patients with lung cancer Woo et al 
showed  that  lung  tumors  contain  large  numbers  of  CD4＋
CD25＋ cells and they have constitutive high-level expression 
of CTLA-4 (110). Furthermore, the CD4＋CD25＋ T cells me-
diate potent inhibition of autologous T cell proliferation, sug-
gesting  they  could  contribute  to  the  progression  of  lung 
cancer. Wieczorek et al found that Treg cell numbers are sig-
nificantly increased in the peripheral blood of patients with 
IL-2-treated melanoma and in formalin-fixed tissue from pa-
tients with lung and colon carcinoma (121). In addition, they 
also demonstrated that Treg cell numbers are predictively ele-
vated in the peripheral blood of patients with various solid 
tumors.  Most  recently,  Qin  et  al  showed  that  pleural  fluid 
from lung cancer patients was chemotactic for Treg cells, and 
intrapleural  administration  of  the  chemokine  CCL22  of  pa-
tients produced a marked progressive influx of Treg cells into 
pleural space, suggesting that CCL22 directly induce Treg cell 
infiltration into the pleural space in patients with malignant 
e f f u s i o n  ( 1 2 0 ) .  T u m o r - a s s o c i a t e d  T  c e l l s  f r o m  p a t i e n t s  w i t h 
early-stage non-small cell lung cancer and late-stage ovarian 
cancer  contain  increased  proportion  of  CD4＋C D 2 5  T  c e l l s 
and may be contributing to T-cell immune suppression (109).
    In patients with breast cancer, the prevalence of Treg cells 
in the peripheral blood of breast and pancreas cancer patients 
is  increased  when  compared  with  normal  individuals. 
Similarly, Treg cells are present in TILs and TDLNs infiltrated 
by  tumor.  These  cells  secret  IL-10  and  TGFβ and  prevent 
activated  CD4＋CD25-  and  CD8＋ from  proliferating  (36). 
Quantification of FoxP3＋ Treg cells in breast cancer is val-
uable  for  assessing  disease  prognosis  and  progression,  and 
Treg  cells  are  an  important  therapeutic  target  for  breast 
cancer. FoxP3＋ Treg cells represent a novel marker for iden-
tifying late-relapse patients (145). Most recently, immunohis-
tochemical  analysis  of  FoxP3  in  primary  breast  tumors 
showed  that  a  high  number  of  tumor-infiltrating  Treg  cells 
within  lymphoid  infiltrates  surrounding  the  tumor  was  pre-
dictive of relapse and death (119). These Treg cells could be 
selectively recruited through CCR4. A most recent study also 
showed that Treg cell are involved in tumor onset and pro-
g r e s s i o n  i n  h u m a n  p r i m a r y  b r e a s t  c a n c e r ,  p o s s i b l y  c o n -
tributing  to  poor  prognosis  of  patients  with  breast  cancer 
(146). A recent study elegantly showed that breast cancer pa-
tients have a greater percentage of circulating Treg cells along 
with serum levels of TGFβ than normal subjects, and that 
HER2/neu peptide (E75) vaccination increased circulating ac-
tivated CD4＋ T cells post-vaccination (147). However, Treg 
cells  were  significantly  reduced  after  vaccination.  Further-
more, activated Treg cells increased. Importantly, post-vacci-
nation  decreases  in  Treg  cells  were  temporally  associated 
with increased E75 vaccine-specific CD8＋ T cells and corre-
sponding HER/neu＋ tumor cytotoxicity. These studies sug-
gest that successful cancer vaccination strategies may require 
the alteration of complex immune interaction. Most recently, 
a study demonstrated that FoxP3 expression in breast cancer 
was associated with worse overall survival probability and the 
risk  increased  with  increasing  FoxP3  immunostaining  inten-
sity.  FoxP3  was  also  a  strong  prognostic  factor  for  distant 
metastases-free  survival.  The  probability  of  10-year  survival 
in node-negative subgroup was 100% for FoxP3-negative and 
82% for FoxP3-positive patients. Authors proposed that FoxP3 
expression as a new independent prognostic factor in breast 
carcinoma, which might help to improve the selection of pa-
tients  for  appropriate  therapy  (148).
Treg cells in hematologic malignancies
The Wilms' tumor gene exerts an oncogenic function in vari-
ous types of leukemias (149). It is also overexpressed in sev-
eral  solid  tumors,  and  therefore,  it  has  been  considered  as Regulatory T Cell in Cancer
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an attractive targer for cancer immunotherapy (149). Recently, 
a  study  demonstrated  that  a  human  HLA-restricted  CD4＋
FoxP3＋ Treg population has been detected in acute myeloid 
leukemia  patients,  suggesting  that  Wilms'  tumor  may  be  a 
novel  target  for  leukemia-specific  CD4＋ Treg  cells  (149). 
Beyer et al demonstrated a significantly increased frequency 
of  CD4＋CD25
high F o x P 3 ＋ Treg  cell  with  strong  inhibitory 
function in the patients with monoclonal gammopathy of un-
determined significance (MGUS) or multiple myeloma (150). 
Prabhala et al also observed a significant increase in CD4＋
CD25＋ T cells in patients with MGUS and in patients with 
multiple  myeloma  compared  with  healthy  donors  (151). 
H o w e v e r ,  T r e g  c e l l s  a r e  s i g n i f i c a n t l y  d e c r e a s e d  i n  p a t i e n t s  
with  MGUS  and  multiple  myeloma  compared  with  healthy 
donors. Moreover, even when they are added in higher pro-
portions, Treg cells in patients with MGUS and multiple mye-
l o m a  a r e  u n a b l e  t o  s u p p r e s s  a n t i - C D 3 - m e d i a t e d  T - c e l l  p r o -
liferation (151). This decrease number and function of Treg 
cells may account, at least in part, for the nonspecific increase 
in CD4＋CD25＋T cells, thereby contributing to dysfunctional 
T - c e l l  r e s p o n s e s .  I n  p a t i e n t s  w i t h  a d u l t  T  c e l l  l e u k e -
mia/.lymphoma  (ATLL),  FoxP3  expression  was  observed  in 
ATLL  cells  (151,153).  In  patients  with  chronic  lymphocytic 
leukemia, increased frequencies of CD4＋CD25
high Treg cells 
have been recently described as an additional mechanism re-
ducing immunity in many patients with cancer (154). More 
recently, Beyer et al assessed 73 patients with chronic lym-
phocytic  leukemia  and  demonstrated  significantly  increased 
frequencies of CD4＋CD25
highFoxP3＋ Treg cells, with high-
est frequencies in untreated or progressing patients presenting 
with  extended  disease  (155).  Most  surprisingly,  in  the  ma-
jority of patients with chronic lymphocytic leukemia treated 
with  fludarabine-containing  therapy  regimens  the  inhibitory 
function of Treg cells was decreased or even abrogated (155). 
In addition, frequencies of  Treg  cells  were  significantly de-
creased after therapy with fludarabine. The authors have pro-
posed that in light of similar findings for cyclophosphamide 
the combination of fludarabine and cyclophosphamide might 
b e  f u r t h e r  e x p l o i t e d  i n  s t r a t e g i e s  r e d u c i n g  i m m u n o s u p p r e -
ssion prior to cancer immunotherapy (155). In patients with 
acute  myeloid  leukemia,  the  frequency  of  CD4＋CD25
high 
T r e g  c e l l s  i n  p e r i p h e r a l  b l o o d  i s  s i g n i f i c a n t l y  h i g h e r  w h e n  
compared with healthy individuals. Notably, Treg cells in pa-
tients  with  acute  myeloid  leukemia  presented  significantly 
higher  apoptosis  and  proliferation  than  that  of  health  in-
dividuals (156). Most recently, it has been reported that Treg 
cell accumulating in the peripheral circulation of acute mye-
loid leukemia patients mediate vigorous suppression via con-
tact-dependent  and  contact-independent  mechanisms  (157). 
Patients with lower Treg cell frequency at diagnosis have a 
better  response  to  induction  chemotherapy.  Unexpectedly, 
patients who achieved complete remission still had elevated 
frequency of Treg cells, which mediated high levels of sup-
pressor activity, suggesting that Treg cell are resistant to con-
ventional chemotherapy (157). Accumulating data have pro-
vided  that  the  presence  of  a  high  number  of  Treg  cells  in 
the solid tumors has been correlated with a poor prognosis 
of patients (25,38,141). However, most of these studies have 
been performed on  carcinomas, with  the role of Treg cells 
in hematologic malignancies such as non-Hodgkin lymphoma 
being less established. Contrary to these observations, Carre-
ras et al reported that follicular lymphoma patients with high-
er Treg cell numbers in their tumors had a better response 
to therapy and improved overall survival (158). In this series 
of follicular lymphoma patients, Follicular Lymphoma Interna-
tional Prognostic Index (FLIPI) effectively segregated the pa-
tients  into  prognostically  relevant  groups.  Interestingly,  the 
prognostic value of the number of Treg cells was indepen-
dent of the FLIPI score, suggesting that this parameter reflects 
a different biologic aspect of the tumors. These studies sug-
gest that the role of Treg cells in the pathogenesis of these 
B-cell  lymphomas  may  be  different  than  carcinomas.  Most 
non-Hodgkin lymphomas are of B-cell origin, but the tumor 
tissue can be variably infiltrated with T cells. A recent study 
showed that a subset of CD4＋CD25＋FoxP3＋with high lev-
el  of  CTLA-4  are  identified  in  biopsy  specimens  of  B-cell 
non-Hodgkin lymphoma and these cells suppressed the pro-
liferation  and  cytokine  (IFN-γ and  IL-4)  production  of  in-
filtrating  CD4＋CD25-  T  cells  in  response  to  phytohemag-
g l u t i n i n  s t i m u l a t i o n  ( 1 5 9 ) .  U s i n g  a  h u m a n  m o d e l  o f  B - c e l l  
non-Hodgkin's  lymphoma,  Yang  et  al  showed  that  intra-
tumoral Treg cells inhibit the proliferation and granule pro-
duction  of  activated  autologous  infiltrating  CD8＋ T  cells 
(160). Moreover, their results showed that degranulation and 
subsequent cytotoxic acivity of infiltrating CD8＋ T cells ex-
posed to lymphoma B cell is completely  attenuated by the 
presence  of intratumoral  Treg cells.  In  patients with Hodg-
kin's lymphoma, Hodgkin lymphoma-infiltrating lymphocytes 
are highly enriched for Treg cells, which induce a profoundly 
immunosuppressive environment for the ineffective immune 
clearance  of  Hodgkin-Reed  Sternberg  cells  (161).  Alvaro  et 
al examined the expression of granzyme B and TIA-1 (mar-Regulatory T Cell in Cancer
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kers  for  cytotoxic  T  lymphocyte)  and  FoxP3  independently 
by immunochemistry in tissue microarray of classic Hodgkin's 
lymphoma  patients  and  correlated  with  patient  outcome 
(162).  They  found  that  low  infiltration  of  FoxP3＋ cells  in 
conjunction  with high  infiltration  of  TIA-1＋ cells in classic 
Hodgkin's lymphoma and this result may represent biological 
markers  predicting  an  unfavorable  outcome.  In  line  with  a 
previous study (161), the presence of FoxP3＋ Treg cells was 
detected in the reactive background of their classic Hodgkin's 
lymphoma  patients.
EFFECTS OF DEPLETION OR REDUCTION OF Treg 
CELLS ON HUMAN TUMOR PROGRESSION
A recent study showed that TILs isolated from patients with 
hepatocellular  carcinoma  are  compromised  and  contain  a 
subpopulation  of  suppressive  CD4＋CD25＋FoxP3＋ Treg 
cells  and  that  functional  deletion  of  tumor-infiltrating  Treg 
cells  could  enhance  tumor-specific  immunotherapy  (163). 
Human CD4＋CD25＋ Treg cells has been isolated from hu-
man peripheral blood, thymus, lymph nodes and cord blood. 
In general, the characteristics of this T cell subset are strik-
ingly  similar  between  mouse  and  man  (164).  Depletion  or 
blockade of Treg cells can also enhance immune protection 
form tumor-associated antigens that are expressed as self anti-
gens (165). A most recent study showed that the relative in-
crease  in  CD4＋CD25＋ T r e g  c e l l s  m a y  b e  r e l a t e d  t o  i m -
munosuppression and tumor progression in patients with gas-
trointestinal cancer (118). In addition, chemotherapy in pa-
tients with advanced disease showed that immunosuppression 
is  enhanced  early  (about  1∼2  weeks)  after  chemotherapy, 
and increased Treg cells 3 weeks after chemotherapy corre-
lated  with  a  poor  prognosis.
    An early study showed that the IL-2 diphtheria toxin con-
jugate DAB389IL-2 (denileukin diftitox, ONTAK) have shown 
clinical activity in a variety of diseases, including B-cell non- 
Hodgkin's lymphoma, cutaneous T-cell lymphoma, Hodgkin's 
disease,  psoriasis,  rheumatoid  arthritis,  and  HIV  infection 
(166).  Moreover,  the  highest  response  rates  were  observed 
in  cutaneous  T-cell lymphoma (166).  This  drug,  denileukin 
diftitox has been approved by the Food and Drug Admini-
stration  in  the  United  States  for  treatment  of  CD25＋cuta-
neous T-cell leukemia and lymphoma (167,168). Dannull et 
al used denileukin diftitox to selectively eliminate CD25-ex-
pressing Treg cells from cancer patients (169). This drug sig-
nificantly reduced the number of Treg cells present in the pe-
ripheral blood of metastatic cell carcinoma patients and abro-
gated Treg cell-mediated immunosuppressive activity in vivo. 
Moreover, they showed that this drug-mediated elimination of 
Treg cells followed by vaccination with RNA-transfected DCs 
significantly improved the stimulation of tumor-specific T cell 
responses in metastatic renal carcinoma patients when com-
pared  with  vaccination  alone.  Their  results  may  have  im-
plications in the design of immune-based strategies that may 
incorporate the Treg depletion strategy to achieve potent anti-
tumor  immunity  with  therapeutic  impact.  It  has  been  ap-
proved for treatment of patients with persistent or recurrent 
cutaneous  T-cell  lymphoma  whose  malignant  cells  express 
the CD25 component of the IL-2 receptor (166,168). A more 
recent  study  indicate  that  denileukin  diftitox  has  activity  in 
the  setting  of  not  only  T-cell  but  also  B-cell  malignancies 
(167). A recent study showed that denileukin diftitoxin was 
a well-tolerated treatments in early- and advanced -stage cuta-
neous  T-cell  lymphoma  and  was  not  associated  with  detri-
mental  immunologic  effects  on  lymphocyte  populations 
(168). Recently, there was a report demonstrating that the hu-
man IL-2 recepotrs exist in three isoforms such as low, inter-
mediate, and high affinity (170). A number of leukemias and 
lymphomas,  including  cutaneous  T-cell  lymphoma,  chronic 
lymphocytic  leukemia,  and  B-cell  non-Hodgkin  lymphoma, 
express a component of the receptors (166). Ex vivo studies 
have  shown  that  denileukin  diftitox  interacts  with  the 
high-and intermediate-affinity IL-2 receptors on the cell sur-
face  and  undergoes  internalization  (170).  Subsequent  clea-
vages in the endosome releases the diphtheria toxin into the 
cytosol, which then inhibits cellular protein synthesis, result-
ing in rapid cell death (29,166,169). The clinical profile and 
potential benefits of denileukin diftitox in the treatment of cu-
taneous T-cell lymphoma were shown (170). More recently, 
a study provided the direct evidence that circulating CD4＋
CD25
highFoxP3＋ Treg cells are depleted after multiple doses 
of immunotoxin, denileukin diftitox and indicated the poten-
tial for combining Treg cell depletion with anticancer vaccines 
to enhance tumor antigen-specific immune response (29). In 
a  series  of  elegant  experiments,  Litzinger  et  al  recently  re-
ported that Treg cells in spleen, peripheral blood, and bone 
marrow of normal C57BL/6 mice were variously reduced after 
a single intraperitoneal injection of denileukin diftitox (171); 
the reduction was evident within 24 hours and lasted approx-
imately 10 days. Injection of denileukin diftitox 1 day before 
vaccination enhanced antigen-specific T cell responses above 
levels  induced  by  vaccination  alone.  These  studies  demon-Regulatory T Cell in Cancer
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strate in murine model (1) the differential effects of denileu-
kin diftitox on Treg cells in different cellular compartments, 
(2) the advantage of combining denileukin diftitox with a vac-
cine to enhance antigen-specific T-cell immune responses, (3) 
the lack of inhibition by denileukin diftitox of host immune 
responses directed against a live viral vector, and (4) the im-
portance of dose scheduling of denileukin diftitox when used 
in combination with vaccine. By application of denileukin dif-
titox in melanoma patients, a recent study showed that deni-
leukin diftitox depletes Treg cell in vivo significantly, resulting 
in enhanced immune functions and substantial development 
of antigen-specific CD8＋ cells in peptide-vaccinated melano-
ma patients after immunization with respective MelanA/MART 
(melanocyte antigen recognized by T cells 1) and gp100 pep-
tides  (43).  Most  recently,  it  has  been  shown  that  Treg  cell 
depletion improves endogenous anti-tumor immunity and the 
efficacy of active immunotherapy in animal models for can-
cer,  suggesting  that  inhibiting  T r e g  c e l l  f u n c t i o n  c o u l d  a l s o 
improve  the  limited  successes  of  human  cancer  immuno-
therapy.  The  strategies  to  block  Treg  activity  have  been 
identified. The fusion toxin denileukin diftitox reduces Treg 
umbers and function in the blood of some patients with can-
cer  (30).  Combining  Treg  cell  depletion  with  active  vacci-
nation  and  other  approaches  pose  additional  challenges.
    Because estrogen regulates Treg cell numbers in mice and 
promotes the proliferation of human Treg cells, Generali  et 
al  investigated  the  immunomodulatroy  effects  of  aromatase 
inhibitor letrozole in breast cancer patients. They found that 
there is a significant reduction in Treg cells in letrozol and 
letrozole-“metronomic” cyclophosphamide patients after trea-
tment  (67).  Importantly,  this  reduction  in  Treg  cells  is  in-
versely related to the response. These novel findings suggest 
that letrozole has a significant immumomodulatory role and 
that aromatase inhibitors could be used in combination with 
other immunotherapeutic approaches. Recently, Powell et al 
have  evaluated  the  Treg  cell  depleting  capacity  of  the 
CD25-directed  immunotoxin,  RFT-SMPT-dgA  and  demon-
strated that administration of RFT5-SMPT-dgA to patients with 
metastatic melanoma induced a transient but robust reduction 
in number of CD25
highCD4 T cells in vivo (172). Using a high-
l y  m e t a s t a t i c  b r e a s t  c a n c e r  m o d e l ,  a  m o s t  r e c e n t  s t u d y  
showed  that  lung  metastasis  required  CCR4＋ Treg  cells. 
Thus strategies that abrogate any part of this process should 
improve the outcome through activation of effector cells and 
prevention  of  tumor  cell  migration.  They  prevented  lung 
metastasis  by  killing  CCR4＋  cells  through  delivery  of 
TARC-fused  toxin  or  depleting  Treg  cells  (173).
    Recently, using a syngeneic intracranial glioblastoma mo-
use model, Curtin et al demonstrated that systemic depletion 
of Treg cells 15 days after tumor implantation using CD25 de-
pleting antibodies (PC61) resulted in a decrease in Treg cells 
present in tumor, draining lymph nodes and spleen and im-
proved long-term survival. No improvement in survival was 
observed when 24 days after tumor implantation, suggesting 
that tumor burden is an important factor for determining effi-
cacy of Treg depletion in clinical trials (174). They noted that 
this approach will be useful in a setting of minimal residual 
disease. Therapeutic modulation of Treg cell populations is 
clinically feasible and will potentially allow the induction of 
effective antitumor immune responses when combined with 
currently available immunotherapeutic strategies (35). Remo-
val of Treg cells via a Bax-dependent apoptotic pathway sig-
nificantly enhances anti-self antigen immune response, which 
demonstrated  the  proof  of  principle  that  apoptosis  of  Treg 
cells is a new therapeutic target (175). Therefore, continued 
characterization of Treg cell apoptosis and homeostasis path-
way would further improve our understanding in regulation 
of immune response by cytokines, hormones and drugs, and 
would also lead to development of new therapeutics. Selec-
tive  separation  of  functional  CD4＋CD25＋ T r e g  c e l l s  f r o m 
large-scale  samples  (patient  leukapheresis  samples)  can  be 
performed in large scale under clinical-grade conditions with 
sufficient selection, recovery, viability, ability to expand, and 
function  for  potential  use  in  adoptive  immunotherapy (68). 
    As described previously, the STAT protein regulate many 
aspects of cell growth, survival and differentiation (133,176). 
Interestingly, constitutive STAT3 has emerged as one of the 
major molecule involved in the mechanisms governing cancer 
immune  tolerance  and  inflammatory  disease.  STAT3  activa-
tion is frequently observed cancer patients. A direct role of 
for STAT3 in mediating the generation of suppressive func-
tions in CD4＋ T cells was raised by a study conducted in 
mice laking SOCS3, which is an inhibitor of STAT3 (133,176, 
177).  In  a  series  of  elegant  experiments,  Pallandre  et  al 
showed that interfering with STAT3 signaling in vitro inhibits 
both iTreg cell conversion and suppressive functions of nTreg 
cells (133).  In vivo, STAT3 knockdown decreases Treg cell 
generation.  Furthermore,  they  showed  that  STAT3  knock-
down enhances antitumor immune response. Therefore, it ap-
p e a r s  t h a t  S T A T 3  s i g n a l i n g  p l a y  a  m a j o r  r o l e  i n  C D 4 ＋ T 
c e l l - m e d i a t e d  i m m u n e  t o l e r a n c e .  A c c o r d i n g l y ,  t h e i r  f i n d i n g s 
determine  that  STAT3  activation  promotes  Treg  cells  gen-Regulatory T Cell in Cancer
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eration and that STAT3 is critical in the molecular pathway 
required for FoxP3 expression (133). The findings also con-
vincingly suggest that STAT3 modulation should be taken into 
account  when  assessing  how  Treg  cells  contribute  to  in-
flammatory diseases and tumor immunosurveillance. The acti-
vation or inhibition of STAT3 may be targeted by pharmaco-
logical  agents  or  microRNA  strategies  to  promote  efficient 
adaptive  immune  responses  to  restore  antitumoral  immune 
responses (133,177). Therefore, it appears that STAT3 signal-
i n g  p l a y  a  m a j o r  r o l e  i n  C D 4 ＋ T  cell-mediated  immune 
tolerance. Evidently, the STAT3 signaling pathway regulates 
cancer metastasis and constitutes a potential preventive and 
therapeutic target for cancer metastasis (176). Recently, there 
was a report that activated STAT3 protein plays a critical role 
in the induction of breast tumor induced by STAT3 knock-
d o w n  4 T 1  c e l l s  i n  i m m u n o c o m p e t e n t  B A L B / c  m i c e  b y  e n -
hancing the expression of several important genes including 
c-Myc and the metastatic regulator Twist (177). These studies 
suggest that stable expression of siRNA for STAT3 has poten-
tial  as  a  therapeutic  strategy  for  breast  cancer.
    Interestingly,  an  early  study  showed  that  Treg  cells  se-
lectively  express  Toll-like  receptor  (TLR)-4,  -5,  -7,  and  -8 
(178).  Exposure  of  Treg  cells  to  the  TLR-4  ligand  lip-
opolysaccharide (LPS) induces up-regulation of several activa-
tion marker and enhances their survival/proliferation. Impor-
tantly, LPS treatment increases CD4＋CD25＋ cell suppressor 
efficiency by 10-fold (178). Peng et al described a mechanism 
linking  TLR8  signaling  to  the  control  of  Treg  cell  function, 
in which synthetic and natural ligands for human TLR8 can 
reverse Treg cell function (179). They also showed that adop-
tive  transfer  of  TLR8  ligand-stimulated  Treg  cells  into  tu-
mor-bearing  mice  enhanced  antitumor  immunity.  Recently, 
new  approaches  to  tumor  immunotherapy  and  vaccination 
have focused on enhancement of effector T cell responses by 
targeting innate immune cells and the receptors that mediate 
their activation. Pathogen recognition receptors, in particular 
TTLRs have been the primary targets for activation of innate 
immune cells (178). Indeed, it has already been demonstrated 
that TLR signaling may directly regulate the suppressive func-
tion of Treg cells and that TLR agonists are potent adjuvants 
for  infectious  disease  antigens  and  have  also  been  used  as 
immunotherapeutic agents in cancer patients (180). Adoptive 
transfer of TLR8 ligand-stimulated Treg cells into tumor-bear-
ing mice enhanced antitumor immunity, suggesting TLR sig-
naling  could  play  a  critical  role  in  controlling  immune  re-
sponse to cancer and other diseases (179). Synthetic oligo-
deoxynucleotides  (ODNs)  that  contain  immunostimulatory 
CpG (cytosine and guanine separated by a phosphate) motif 
(CpG  ODN)  trigger  an  immunomodulatory  cascade  (19). 
Jarnickie  et  al d e m o n s t r a t e d  t h a t  T L R  l i g a n d s  a l s o  p r o m o t e  
the induction of IL-10 secreting Treg cells and a p38 inhibitor 
suppresses the generation of Treg cells and enhances the anti-
tumor  therapeutic  efficacy  of  DCs  pulsed  with  antigen  and 
CpG (19). Furthermore, they reported that attenuating Treg 
cell  induction  by  TLR  agonists  LPS,  poly  (I：C)  or  CpG 
through inhibition of p38 MAPK signaling in DCs enhances 
their  efficacy  as  vaccine  adjuvants  and  cancer  immunother-
apeutics,  providing  evidence  that  p38  is  an  important  ther-
apeutic  target.
    Radiofrequency thermal ablation (RFTA) is a minimally in-
vasive technique that has prove to be effective in the treat-
ment of nonsurgical patients with liver cancer (28). This treat-
ment destroys tumor tissue by delivering a high-frequency al-
ternating  current  with  ionic  agitation  and  frictional  heating. 
As a consequency, cell membrane alteration, protein denatu-
ration, and necrosis around electrode are produced and large 
amounts  of  tumor  and  tissue  debris  are  released  (28).  Of 
great interest, using this RTTA, in a series of elegant studies, 
Fietta et al assessed whether RFTA could affect multiple sys-
temic inflammatory and immunological parameters, including 
CD25＋FoxP3＋ Treg cells in patients with primary or meta-
static lung tumors (28). They demonstrated that 3 days after 
RFTA, a moderate and temporary systemic inflammatory re-
s p o n s e  d e v e l o p e d .  M o r e o v e r ,  3 0  d a y s  a f t e r  R F T A ,  a  s i g -
nificant reduction in CD25＋FoxP3＋ cell counts with an in-
crease in CD4＋ T-cell proliferation was observed. The reduc-
tion  in  CD25＋FoxP3＋ c e l l s  l a s t e d  u p  t o  9 0  d a y s  a f t e r  
treatment. The use of RFTA in lung cancer patients has an 
immunomodulatory activity. They also reported that in addi-
tion to tumor ablation, downmodulation of Treg cells might 
be an important mechanism involved in the long-term clinical 
efficacy  of  RFTA.  Their  findings  suggest  that  the  small  but 
significant reduction of the peripheral CD25＋FoxP3＋ Treg 
cell pool might be of functional importance in improving host 
T-cell reactivity. Further analysis on a large series of cancer 
patients will be required to carry out to corroborate these pre-
liminary  results.
THERAPEUTIC VACCINATION
Prophylactic cancer vaccines have been effective in a number 
of spontaneous tumor models in mice, including models of Regulatory T Cell in Cancer
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breast, prostate, and colon cancer (3). In cancer patients, vac-
cination strategies have been limited to advanced disease and 
many strategies for generating therapeutic immune response 
to cancer have been attempted (3). An early study showed 
t h a t  s i g n i f i c a n t  i n c r e a s e s  i n  t h e  n u m b e r  o f  a n t i g e n - s p e c i f i c  
CTL in circulation after immunization of melanoma patients 
with  peptides  or  melanoma  tumor  lysate-loaded  with 
APC-based vaccines (181). A recent study showed that vacci-
nation of mice with FoxP3 mRNA-transfected DCs elicited a 
robust  FoxP3-specific  CTL  response  and  potentiated  vac-
cine-induced  protective  immunity  (182).  Importantly,  FoxP3 
vaccination led to the preferential depletion of FoxP3-expre-
ssing Treg cells in the tumor but not in the periphery, where-
as αCD25 antibody treatment led to depletion of Treg cells 
in both the tumor and the periphery. These studies strongly 
indicate that depletion of Treg cells by treatment with αCD25 
antibody  may  synergize  with  vaccination  protocols  to  en-
gender protective immunity in mice. A recent study elegantly 
showed that breast cancer patients have a greater percentage 
of  circulating  Treg  cells  along  with  serum  levels  of  TGFβ 
than normal subjects, and that HER2/neu peptide (E75) vacci-
nation increased circulating activated CD4＋ T cells post-vac-
cination  (147).  However,  Treg  cells  were  significantly  re-
duced  after  vaccination.  Importantly,  post-vaccination  de-
creases  in  Treg  cells  were  temporally  associated  with  in-
creased E75 vaccine-specific CD8＋ T cells and correspond-
ing HER/neu＋ tumor cytotoxicity. These studies suggest that 
successful cancer vaccination strategies may require the alter-
ation  of complex  immune interaction.  A more recent study 
reported  that  melanoma  patients  receiving  a  MAGE-A3.DP4 
peptide vaccine can produce CD4＋ T cells that may exert 
Treg  cell  function  in  vivo  (183).  NY-ESO-1  is  a  180  ami-
no-acid  human  tumor  antigen  expressed  by  “cancer-testis” 
antigen (20). In human, NY-ESO-1 is a highly immunogenic 
tumor antigen expressed in a variety of malignancies, making 
it an excellent target for cancer vaccination (20). Nicholaou 
et al recently developed a vaccine consisting of full-length re-
combinant  NY-ESO-1  protein  formulated  with  ISCOMATRIX 
adjuvant, which generated humoral and T-cell-mediated im-
mune  responses  and  seemed  to  reduce  the  risk  of  disease 
relapse in patients with fully resected melanoma (20). They 
examined  the  clinical  and  immunologic  efficacy  in  patients 
with advanced metastatic melanoma. They found that in con-
trast  to  minimal  residual  disease,  advanced  melanoma  pa-
tients showed no clinical responses to vaccination. Although 
strong antibody responses were mounted, the generation of 
delayed-type  hypersensitivity  response  was  significantly  im-
p a i r e d  a n d  p a t i e n t s  w i t h  a d v a n c e d  m e l a n o m a  h a d  a  s i g -
nificantly  higher  proportion  of  circulating  CD4＋CD25＋
FoxP3＋ Treg cells compared with those with minimal residual 
disease. Their results point to a tumor-induced systemic im-
mune suppression, showing a clear association between the 
stage of melanoma progression, the number of Treg cells in 
the blood, and the clinical and immunologic efficacy of the 
NY-ESO-1SCOMATRIX  cancer  vaccine  (20).  Interestingly,  a 
most recent study demonstrated that only Treg cell depletion 
followed by neu DNA vaccination abrogated tolerance to neu 
(rat  erbB-2),  resulting  in  complete  regression  of  neu＋ tu-
mors, as well as long-term protection from spontaneous tu-
morigenesis (184). In addition, in mice with induced tumor 
regression, mouse thyroglobulin response was enhanced with 
modest  increases  in  autoimmune  thyroiditis.  These  studies 
strongly suggest that tumor regression induced by Treg cell 
depletion and DNA vaccination can exacerbate autoimmunity. 
Therefore,  patients  undergoing  immunotherapy  should  be 
closely  monitored  for  signs  of  autoimmune  symptoms.
PROGNOSTIC VALUE OF Treg CELLS IN PATIENTS 
WITH CANCER
A better prognosis was observed in patients with a low preva-
lence of Treg cells and a high prevalence of Treg cells seems 
to be a marker of poor prognosis in pancreatic ductal carcino-
ma (185). A recent study also showed that in patients with 
undesirable outcome the balance is tipped in favor of Treg 
cells, whereas in patients with relatively desirable outcome, 
the balance is tipped toward effector T cells, suggesting that 
Treg  cells  are  associated  with  hepatocellular  carcinoma  in-
vasiveness, and  intratumoral balance  of regulatory  and CTL 
is a promising independent predictor for recurrence and sur-
vival in hepatocellular carcinoma (124). A combination of de-
pletion of Treg cells and concomitant stimulation of effector 
T  cells  may  be  an  effective  immunotherapy  to  reduce  re-
currence and prolong survival after surgery. The patients with 
high expression of CD4 or CD8 had distinctly worse cancer 
specific overall survival (38). The analysis of tumor-infiltrating 
immune cells may be a valuable prognostic tool and a marker 
of  lymph  node  involvement.  Shevach  reported  that  an  ele-
vation  in  the  number  of  tumor  Treg  cells  was  a  significant 
predictor  of  patients  death,  even  after  controlling  for  stage 
of disease and surgical reduction of tumor mass (186). In ad-
dition,  one  line  of  evidence  showed  that  the  presence  of Regulatory T Cell in Cancer
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FoxP3＋ cells within tumors has been shown to be predict 
the prognosis, invasiveness, and metastatic ability of some tu-
mors by modulating the ability of the immune system to tar-
get tumor cells. The widespread use of FoxP3 as a biomarker 
should be explored for human tumors to enable physicians 
to  make  better  decisions  in  oncologic  care  and  to  prepare 
the  filed  of  novel  therapeutic  agents  directed  at  the  elimi-
n a t i o n  o f  T r e g  c e l l s  w i t h i n  t u m o r s  ( 3 9 ) .  F o x P 3  e x p r e s s i o n  
might be related to the metastatic potential of the tumor rath-
er than to suppression of a specific immune response (187). 
The  findings  that  FoxP3  can  be  expressed  by  not  only  tu-
m o r - i n f i l t r a t i n g  T r e g  c e l l s  b u t  a l s o  t u m o r  c e l l s  h a s  t w o  i m-
portant  implications  (187).  First,  increased  levels  of  FoxP3 
mRNA expression may be a result of not only an increased 
influx of Treg cells but also the increase expression of FoxP3 
directly  in  tumor  cells.  Second,  we  need  to  recognize  that 
FoxP3-targeted therapy may need to be targeted at not only 
Treg cells but also FoxP3-positive tumor cells. The expression 
of FoxP3 in tumor cells indicates that FoxP3-targeted drugs 
must to be able to penetrate into the tumor, which is much 
more  challenging  than  depleting  FoxP3  in  the  periphery 
(187). FoxP3 remains an accurate marker to define primary 
T r e g  c e l l s  i n  p a t i e n t s  w i t h  c a n c e r  a n d  a u t o i m m u n e  d i s e a s e  
(188). The authors suggest that the combination of FoxP3 and 
cytokine profile is useful for further functionally distinguish-
ing  primary  Treg  cells  from  activated  conventional  T  cells. 
Most recently, a study demonstrated that FoxP3 expression in 
breast  cancer  was  associated  with  worse  overall  survival 
probability and the risk increased with increasing FoxP3 im-
munostaining intensity (148). FoxP3 was also a strong prog-
nostic factor for distant metastases-free survival. The proba-
bility of 10-year survival in node-negative subgroup was 100% 
for  FoxP3-negative  and  82  %  for  FoxP3-positive  patients. 
Authors proposed that FoxP3 expression as a new indepen-
dent prognostic factor in breast carcinoma, which might help 
to improve the selection of patients for appropriate therapy 
(148). In malignancies of intrinsic central nervous system, in-
terestingly, Heimberger et al have recently shown that Treg 
infiltration differed significantly in the tumors according to lin-
eage,  pathology,  and  grade,  and  that  Treg  cells  seemed  to 
have the highest predilection for tumors of the astrocytic line-
age and specifically in the high-grade gliomas, such as glio-
blastoma multiforme (41). Intratumoaral FoxP3-positive regu-
latory immune cells significantly increased during IL-2-based 
immunotherapy,  and  high  numbers  of  on-treatment  FoxP3- 
positive cells were correlated with poor prognosis in patients 
with  metastatic  renal  cell  carcinoma  (139).
    In  marked contrast  to  the  poor prognostic value of  Treg 
cell presence in these tumors, some current studies demon-
s t r a t e d  t h a t  d i s e a s e  s p e c i f i c  s u r v i v a l  w a s  n o t  i n f l u e n c e d  b y  
the presence of FoxP3＋ Treg cells in ovarian tissue, but me-
dian disease specific survival of patients with a high CD8＋/ 
FoxP3＋ ratio in ovarian-derived tumor tissue was twice as 
high as for patients with a low CD8＋/FoxP3＋ ratio (141). 
Possibly, the positive prognostic effect of the of FoxP3＋ cells 
in their samples can be attributed to the staining of not only 
suppressive,  but  also  activated  T  cells  expressing  FoxP3. 
Furthermore, a widely used model for human colorectal carci-
nogenesis  is  the  multiple  intestinal  neoplasia  (Min)  mouse, 
which has a germ-line mutation in the Apc tumor suppressor 
gene  (Apc
Min).  Interestingly,  a  recent  study  has  shown  that 
adoptive immunotherapy using CD4＋CD25＋ Treg cells pre-
vents  the  development  of  intestinal  tumors  and  rapidly  in-
duces regression of established tumors in the Apc
Min/＋mouse 
model of human intestinal cancer (185). Surprisingly, a study 
reported that FoxP3＋ Treg cell density in normal and tumor 
tissue had stronger prognostic significance in colorectal can-
cer compared with CD8＋ and CD45RO＋ lymphocytes. The 
authors reported better survival associated with a high density 
of intratumoral FoxP3＋ Treg cells in colorectal cancer (26). 
In patients with follicular lymphoma and Hodgkin's lympho-
ma,  it  is  now  well  established  that  high  number  of  intra-
tumoral Treg cells is associated with longer disease-free and 
overall survival. This correlation between the number of Treg 
c e lls  an d f av or ab le  cl in ic al o u tc o me  h as a lso  re c en t ly  be e n 
extended in some solid tumors (189). In patients head and 
neck  cancer,  the  authors  found  that  tumor  infiltration  by 
FoxP3＋CD4＋ Treg cells was positively associated with bet-
ter locoregional control of the tumor. In addition, multivariate 
analysis showed that the only significant prognostic factors re-
lated to locoregional control was T stage and Treg cell infiltra-
tion of the tumor (190). Frequency of FoxP3＋CD4＋ Treg 
cells has been shown to be higher in patients with no evi-
dence of disease after oncologic therapy than in patients with 
active  disease  (123).  These  results  were  surprising,  and  in 
marked  contrast  to  the  poor  prognostic  value  of  Treg  cell 
presence in other tumors as described previously (40,91,125, 
139,148,190,191). Interestingly, a recent study showed that it 
is  the  Foxp3-  subset  of  CD4＋CD25＋ T  cells  and  not  the 
FoxP3＋ subset that correlated with worse pathologic feature 
of  renal  cell  carcinoma  and  cancer-specific  survival  (40). 
V a r i o u s  p a r a m e t e r s  m a y  e x p l a i n  t h e s e  s e e m i n g l y  c o n t r a -Regulatory T Cell in Cancer
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dictory results regarding prognostic value of Treg cells in pa-
tients with cancer. First, the role of Treg cells seems to differ 
according to tumor stage (192). Second, it is not surprising 
that various studies have reported that the ratio of CD8＋ T 
cell to Treg cells had more important on patient survival than 
the  number  of  Treg  cells  or  intraepithelial  CD8＋ T  cells 
alone (124). Third, unlike in mice, FoxP3 expression is not 
confined  to  certain  population  in  humans  (187).
A VIEW TO THE FUTURE
The pathophysiological role of tumor-infiltrating CD4＋ Treg 
cells remains less understood than that of CD4＋ Treg cells. 
H o w e v e r ,  r e c e n t l y ,  a  s t u d y  s h o w e d  t h a t  t h e  c o n v e r s i o n  o f  
CD8＋ effector T cells into suppressor cells in tumor micro-
enviroment and tumor restrict the immune response from ef-
fectively controlling tumor growth (193). As subsequent effec-
tors  infiltrate  the  tumor,  the  tumor-induced  Treg  cells  may 
suppress these new effectors and reduced their ability to con-
fer tumor immunity. This cyclic suppressive process may con-
tribute to the profound loss of antitumor response following 
immunotherapy. New approachs to block these pathway will 
enhance our ability to generate more sustained and effective 
antitumor  T  cell  response  (193).  Most  recently,  one  study 
showed that blocking TGFβ in a tumor-bearing mice can in-
hibit  the  induction  of  highly  suppressive  tumor-sensitized 
Treg cells, indicating that TGFβ blockade may improve the 
generation of therapeutic immune responses in patients with 
cancer (194). As already outlined, FoxP3 is a key transcription 
factor for development and function of nTreg cells. Most re-
cently, Sakaguchi group reported that human FoxP3＋CD4＋ 
T cells were composed of three phenotypically and function-
ally  distinct  subpopulations  (195):  CD45RA＋FoxP3
lo r e s t i n g 
Treg cells (rTreg cells) and CD45RA-FoxP3
high activated Treg 
cells  (aTreg  cells)  and  cytokine-secreting  CD45RA-FoxP3
lo 
nonsuppressive  T  cells.  They  noted  that  the  dissection  of 
FoxP3＋ cells into subsets enables one to analyze Treg cell 
differentiation dynamics and interactions in normal and dis-
ease states, and to control immune response through manipu-
lating particular FoxP3 subpopulations. Currently, one study 
showed  that  MHC  class  II  expression  identifies  an  effector 
subset of human CD4＋CD25
high FoxP3
high natural T cells (DR
＋ Treg cells) that induces more rapid suppression and ex-
hibits higher FoxP3 expression than the remaining Treg pop-
ulations (196). This paper reported that responder cells ac-
tively  kill  effector  Treg  cells p r o d u c i n g  g r a n z y m e  B  i n  r e -
sponse to strong TCR stimulation. These data demonstrate a 
novel  role  for  granzyme  B  to  down-regulate  effector  DR＋ 
Treg  cell  function.
    Intriguingly, multiple investigators have shown that micro-
RNA (miRNA)-mediated RNA interference has been identified 
as a novel  mechanisms  that  regulates protein  expression  at 
the  transcription  level  (197-199).  Furthermore,  recent  pub-
lications have provided compelling evidence that a range of 
miRNAs are involved in the regulation of immune responses, 
including  the  development  and  differentiation  of  B  and  T 
cells,  especially  Treg  cells  (198-200).  In  the  absence  of 
miRNAs, FoxP3＋ Treg cell develop but fail to maintain im-
mune homeostasis, leading to a scurfy-like disease. In addi-
tion,  miRNA-155  deficient  mice  have  reduced  numbers  of 
Treg cells, both in thymus and periphery (200,201). A most 
recent  study  showed  that  FoxP3  controlled  the  elevated 
miR155  expression  required  for  maintaining  Treg  cell  pro-
liferative activity and numbers under non-lymphopenic con-
ditions,  suggesting  FoxP3-dependent  regulation  of  miR155 
maintain competitive fitness of Treg cell subset by targeting 
SOCS1 protein, a negative regulatory of the IL-2 signaling cas-
cade  (197). Overall, there is now compelling evidence that 
miRNAs  are  involved  in  the  regulation  of  the  immune  re-
sponse, and modulation of their activity might ultimately pro-
v i d e  a  n o v e l  t h e r a p e u t i c  a p p r oach  in  the  treatment  of  in-
flammatory  disease  and  certain  cancers  (197,200,202).
    The ability to overcome some of the limitations of Treg cell 
therapy  by  genetically  re-programming  Treg  cells  is  poten-
tially  attractive.  Lastly,  as  our  knowledge  of  Treg  cell  im-
mune-suppressive  mechanisms  increases,  additional  oppor-
tunities to enhance or inhibit Treg cell function via gene ther-
apy will be encouraging. It is becoming increasingly clear that 
a major component of the next wave of therapeutic agents 
that will attempt to tackle our unmet medical needs will be 
Treg cell and gene therapy. Indeed, Treg cell therapy has the 
promise of avoiding many of the toxicities observed with cur-
rent drug regimens. This potential will be realized too early.
CONCLUSION
It is now absolutely clear that there now exists overwhelming 
evidence from both human and animal studies that regulatory 
T cells play an active and significant role in the progression 
of cancer, and that regulatory T cells have an important role 
in suppressing tumor-specific immunity. Thus, there is a clear 
rationale  for  developing  clinical  strategies  to  diminish  there Regulatory T Cell in Cancer
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Figure 2. Therapeutic targeting of 
regulatory T cells. The patients with
cancer might be subjected to 
traditional tumor therapy, conven-
tional immunotherapy and/or novel
tumor immunotherapy. To attain 
more effective, reliable and con-
sistent clinical efficacy, it might be 
essential to apply combinatorial 
therapy. APC, antigen presenting 
cell; CTLA4, cytotoxic T-lympho-
cytes-associated antigen 4; PD1, 
programmed cell death; COX2, 
cyclooxygenase.
regulatory  influences,  with  the  ultimate  goal  of  augmenting 
antitimor immunity. Therefore, manipulation of Treg cells, in-
cluding  depletion,  blocking  trafficking  into  tumors,  or  re-
ducing their differentiation and suppressive mechanisms, rep-
resent new strategies for cancer treatment. It should be men-
tioned that although this review has focused on one of the 
most well characterized regulatory T cell types, many other 
subsets including Tγ1, Th3, CD8＋ regulatory cells, CD4＋ 
cells  that  show  features  of  both  natural  and  adaptive  Treg 
cells, and γδ T cells have been reported. Thus, future chal-
lenge  include  the  identification  of  unique  regulatory  cell 
m a r k e r s  t h a t  c a n  b e  u s e d  t o  m o r e  s p e c i f i c a l l y  t a r g e t  t h e s e  
cells in vivo and a more accurate characterization of the mo-
lecular  nature  of  immune  suppression.  Therapeutically, 
agents that can selectively and efficiently target Treg cells de-
serve extensive research. Survival is the most important end-
point for evaluating cancer therapy. For the last 50 years cyto-
toxic chemotherapy has been one of the mainstay of cancer 
treatment. While the ability of chemotherapy treatment to in-
duce tumor control and remission has continued to improve 
(notably  in  the  hematological  malignancies),  chemotherapy 
often fails to prevent disease recurrence. Successful combina-
tion of chemotherapy plus radiotherapy with immunotherapy 
would appear to be the best way forward for improving the 
ability of chemotherapy- based treatments to prevent disease 
recurrence  and  increase  cure  rates  of  many  malignant  dis-
eases. Although targeting Treg cells is an attractive option in 
treating human tumors and “all anyone is talking about these 
days is regulatory T cells”, it is probable that a complicated 
combinatorial therapeutic regimen of traditional tumor ther-
apy and conventional immunotherapy combined with novel 
tumor immunotherapy, including targeting Treg cell (chemor-
adiosurgicoimmunotherapy) would appear to be the best way 
forward  to  obtain  effective,  reliable  and  consistent  clinical 
efficacy. Researchers, clinical immunologists and oncologists, 
together,  should  make  efforts  to  design  combined  chemo-
radioimmunotherapy strategies (see Fig. 2). However, there 
are still many unanswered questions. While the road is not 
straight and smooth, there are challenge and great promise 
and excitement over the horizon. It will address both chal-Regulatory T Cell in Cancer
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lenge  and  opportunities  in  human  Treg  cell  therapy.  Only 
time and hard work will answer many questions we are now 
confronting.
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